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ABSTRACT

TIMOTHY CHARLES BALL. Characterization of Early B-Lymphopoiesis: The
Differentiation of Lymphohemopoietic and Early Committed B-Lymphoid Progenitors.
(Under the direction of Dr. MAKIO OGAW A)

Studies of B-Iymphopoiesis have long been hindered by the lack of assays capable
of supporting the differentiation and identification of lymphohemopoietic and early
committed B-Iymphoid progenitors. The clonal identification of cell-cycle dormant
lymphohemopoietic progenitors from mice treated with 5 flurouracil (5-FU) became
possible with the development of the two-step assay for lymphohemopoietic progenitors.
Studies presented in this dissertation are centered around elucidation of the processes of
differentiation of lymphohemopoietic progenitors in an attempt to detennihe the sequence of
events occurring in divergence of the B-Iymphoid and myeloid lineages. To address this
question a single-step assay capable of supporting the differentiation of proliferating
lymphohemopoietic and early committed B-lymphoid progenitors was developed. This
assay makes use of semisolid methylcellulose culture, in situ microscopic examination and
flow cytometric analysis to identify progenitors with lymphohemopoietic and B-lymphoid
potential. Using this assay the lymphohemopoietic progenitors present in normal mice
were characterized, and of these, approximately 75% were found to be sensitive to the
cytotoxic effects of 5-FU. The proliferation and commitment of primitive
lymphohemopoietic progenitors was then examined, and found to proceed through 3 stages
a lymphohemopoietic proliferative stage, a commitment stage and an early committed Blymphoid proliferative stage. Finally using a modified version of the two-step assay, the

lineage potential of individual lineage negative Ly 6A/E (Sea-I) positive progenitors from
normal mice were examined. Assuming the culture system is equally permissive for the
differentiation of all myeloid lineages, the results support a model of random restriction of
lineage potential with a late divergence of the B-Iymphoid and the myeloid lineages,
possibly resulting in the formation of a bipotential B-Iymphoidlmacrophage progenitor.

Chapter I
General Introduction
Timothy C. Ball
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INTRODUCTION

Hemopoiesis is the process of the formation of the eight different types of mature
blood cells from small a population of primitive stem cells. Hemopoietic stem cells are the
most primitive of hemopoietic progenitor cells. They have the capability to give rise to all
hemopoietic cells as well as having unlimited self-renewal capacity. Hemopoiesis has been
subdivided into myelopoiesis, the production of myeloid lineage cells, and lymphopoiesis,
the production of lymphoid lineage cells. The cells composing the myeloid lineage are
monocytes/macrophages, megakaryocytes, erythrocytes and granulocytes. Three types of
cells are classified as granulocytes based on their extremely well developed cytoplasmic
granules: neutrophils, eosinophils and basophils. B- and T-Iymphocytes comprise the
lymphoid lineage. The designation of B- and T -lymphocytes was based on the recognition
that the bursa of Fabricius, first described by Fabricius in 1621 (1), is the site of Blymphopoiesis in birds as is best reviewed by Warner et al. (2). T-Iymphopoiesis takes
place in the thymus (3). Pluripotent cells are cells that have the capacity to generate the
entire complement of myeloid and lymphoid lineage cells. Pluripotent stem cells reside in
the bone marrow, and bone marrow is the normal site of both myelopoiesis and Blymphopoiesis (4-7).
A brief discussion of the most important and commonly used terminology will now
be presented in an attempt to ensure a clear understanding of the presented concepts, in
addition, Table 1-1 has been provided as a handy reference for explanation of the
terminology used throughout this text. As mentioned, a lymphohemopoietic progenitor is a
progenitor that has the potential to give rise to cells of both the lymphoid and myeloid
lineages. Since this study is limited to the B-Iymphoid lineage, T-Iymphoid potential,
although important will not be considered. A progenitor is any cell that has proliferative
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capacity, or the ability to give rise to a daughter cell. A terminally mature erythrocyte or
neutrophil that no longer has the capacity to divide cannot be designated a progenitor.
Progenitors can be additionally described as primitive or mature. These terms are used to
describe the relative position of a progenitor in the hierarchy of differentiation. A restricted
progenitor is a progenitor that is believed to be past the point of no return, or restricted to a
certain fate. Thus a B-Iymphoid restricted progenitor is one that is restricted to the
production ofB-lymphoid lineage cells, while a myeloid restricted progenitor can only give
rise to myeloid lineage cells. The teffil stem cell is commonly used in referring to a cell
with an extended capacity to self-renew as was done by Abramson (8). In my discussion,
I will use the term stem cell very cautiously to denote only cells with unlimited capacity to
self-renew and form mature cells of all hemopoietic lineages.
In 1956, Ford demonstrated donor bone marrow transplanted into an irradiated host
reconstituted the hemopoietic system generating a chimera (9). However, it was not until
1977, that Abramson et al. unequivocally demonstrated the existence of a pluripotent
hemopoietic stem cell capable of generating functional mature cells of both the myeloid and
lymphoid lineages (8). This was achieved following the procedure ofWu et ala (10),
generating chromosomal aberrations in stem cells with mild irradiation and reconstituting
lethally irradiated mice with these mildly irradiated cells. The mice were then sacrificed and
their bone marrow, spleen, lymph nodes and thymus were examined for the expression of
functional mature B, T and myeloid lineage cells with identical chromosomal markers.
Abramson injected irradiated donor marrow preparations into a total of 28 recipient mice
and examined the resultant progeny 8 to 12 months after transplantation. A total of 10 mice
were found to have high concentrations of marked cells. Of the 10 mice, 5 were found to
have identically labeled cells in both the myeloid and the lymphoid lineages, while in three,
only marked myeloid lineage cells could be identified and in the remaining 2 marked cells
limited to the T -lymphoid lineage were found. Prior to designating the progenitors
"restricted" they were transferred into secondary recipients to ensure that they continued to
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demonstrate limited lineage expression. After ruling out artifacts such as stochastic
variation and irradiation induced leukemia, restriction of lineage potential and aberration of
pluripotent stem cells, the conclusion was drawn that they had isolated pluripotent, myeloid
and T -lymphoid restricted stem cells. With their demonstration of pluripotent, myeloid and
T-Iymphoid restricted stem cells, a view of hemopoietic differentiation that envisioned an
extremely early divergence of the lymphoid and the myeloid lineages was accepted, Figure
1-1. Since then, several investigators have corroborated the observations of Abramson,
demonstrating the existence of pluripotent, myeloid and T -lymphoid restricted stem cells
(11-13). In 1980, Harrison developed the competitive repopulation assay in which lethally
irradiated mice are reconstituted with two different populations of marrow, a known
competitor and an unknown donor population, that can be readily differentiated (14).
U sing simple statistical analyses of the resultant data and mathematical modeling, biological
phenomenon regarding the repopulation of the hemopoietic system can be inferred. For
example, by examining the correlation between T cell, B cell, granulocyte and platelet
production by progenitors transplanted into recipient mice, inferences of the lineage
potential of the progenitors is possible. In short, their analyses revealed no significant
evidence of repopulation by lymphoid or myeloid restricted progenitors at any time after
transplantation (15, 16). In all actuality, this assay may also produce more true to life
results than other assay systems due to the reduction in purification trauma and
environmental stress to which the progenitors are subjected prior to transplantation. Still,
the conventional view of hemopoietic differentiation in which primitive lymphohemopoietic
progenitors give rise to myeloid and lymphoid restricted progenitors holds.
In examining the process of B-Iymphopoiesis, two investigators have developed
models of B-lymphopoiesis that are contradictory to the conventional view of hemopoiesis.
Davidson et al. in 1988 examined the relationships between B-Iymphoid and macrophage
differentiation using a transformed bone marrow derived cell line that coexpressed the Ly1, B220 and Mac-l antigens. B220 and Mac-l are believed to be specific for cells of the
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B-Iymphoid and the macrophage lineages, respectively_ They determined that individual
cells of this cell line were capable of giving rise to Ly-l + B220+ B cells and functional Ly1+ Mac-l + macrophages. These bipotential Ly-l +, B220+ and Mac-l + progenitors are
believed to give rise to the Ly-l + subset of B cells which reside primarily in the pleural,
pericardial and peritoneal cavities. With these observations they developed a model in
which lymphohemopoietic progenitors give rise to bipotential B-IymphoicVrnacrophage
progenitors which in turn generate functional Ly-l + B cells and macrophages (17).
Cumano et al. developed another model of B-Iymphopoiesis after their identification
of a population of bipotential B~lymphoicVmacrophage progenitors in the livers of fetal mice
that were a discreet population separate from the population of lymphohemopoietic stem
cells (18). As in the model of Davidson et al. they also postulate the existence of a
bipotential B-Iymphoid macrophage progenitor. According to their model, there are seven
phases of development through which a lymphohemopoietic progenitor passes in the
generation of a functional immunoglobulin secreting plasma cell. In their model, phase I
begins with a primitive lymphohemopoietic progenitor present in a developing fetus that
gives rise to bipotential B-Iymphoid/macrophage progenitors. In this phase the
lymphohemopoietic progenitors can be identified by their expression of the AA4 antigen.
In culture, these cells require the synergistic interaction of IL-Il in combination with c-kit
ligand to initiate and support their proliferation and differentiation. Phase II of
differentiation is composed of bipotential B-IymphoicVmacrophage progenitors that express
AA4 and Ly-6A antigens. These cells also proliferate and differentiate in the presence of
IL-l1 and SF. Phase II cells, then give rise to B-Iymphoid restricted progenitors that are
dependent on the synergistic interaction of SF and IL-7 to support continued proliferation
and differentiation and macrophage progenitors. It is in Phase III, that the expression of
the pan-B cell antigen, B220, occurs. As B-Iymphoid progenitors enter phase IV, they
loose their responsiveness to IL-7, and the transition into phase V is marked by the
expression of surface IgM. The remaining phases of B-Iymphopoiesis are of very late
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stage B cell progenitors, and are beyond the scope of this discussion. Thus, although the
conventional view of hemopoiesis, with its early divergence of the lymphoid and myeloid
lineages is the most widely accepted model of hemopoiesis, models of B-Iymphopoiesis
incorporating a tangible bipotential B-Iymphoid/macrophage progenitor also exist.
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CHARACTERIZATION OF B-LYMPHOPOIESIS.

The progression of the characterization ofB-lymphopoiesis from the early 1970's
to present is shown in Figure 1-2. One of the more striking features of this figure is the
advancement in the identification and characterization of progressively more primitive Blymphoid progenitors over time. Initially using sedimentation velocity, Miller et al. (19)
characterized the progenitor B (PB), B 1 and B2 stages of B cell differentiation, all of which
were positive for the expression of surface immunoglobulin. Hammerling et al. (20)
examined the expression of the inducible immunoglobulin (Ig), immune response antigen
(Ia) and C3 complement receptor (CR) surface antigens and further modeled Blymphopoiesis by surface Ig+ cells. Coffman et al. (21) and Kincade et al. (22) were able
to advance the study B-Iymphoid progenitors to the level of those progenitors that were
negative for the expression of surface Ig by isolating monoclonal antibodies to B220.
Finally, Hardy et al. (23) focused on characterizing the substages of B-Iymphoid
progenitors positive for the expression of B220. In this characterization, based on the
expression, or lack thereof of, B220, CD43, HSA and BP-l surface antigens, 5 distinct
substages: A, B, C, C' and D were identified. By identifying such specific
subpopulations, examination of the immunoglobulin gene rearrangement status resulted in a
clear characterization of the progression of this process.

Surface Ig+ progenitor B cells and their differentiation.
In 1972 Lafleur developed the first quantitative assay for B-cell precursors, the PB
cell assay (24). The in vitro PB cell assay requires first, that populations of B cell
progenitors be injected into lethally irradiated mice. Seven days after transplantation, the
mice are immunized intraperitoneally with sheep erythrocytes. Eight days after
immunization the mice are sacrificed and the number of plaque forming cells (PFC) per
spleen is detennined. The number of PFC per spleen is directly proportional to the number
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of PB cells initially injected. Similarly, other populations of progenitors can be assayed for
their potential to give rise to mature antigen responsive B-cells by modifying the duration of
time between transplantation and antigenic challenge.
While studying the characteristics of PB cells, it was found that they were positive
for the expression of surface immunoglobulin but were not responsive to antigenic
challenge. Closer examination of the B cell progenitors revealed the presence of an
intermediate B cell progenitor with a sedimentation velocity between that of the PB cells
and mature B cells. These intennediate cells were designated B 1 cells while mature B cells
were designated B2 cells (25). These investigations led to the characterization of the
progression ofB-lymphopoiesis from a surface Ig+ progenitor B (PB) cell to an antigen
responsive B cell progenitor (B 1) cell to a mature (B2) cell (26).

Expression of inducible surface antigens.
Hammerling analyzed the expression of 3 inducible surface antigens
immunoglobulin (Ig), the antigen associated with the immune response gene (Ia) and the
complement C3 receptor (CR) in an attempt to characterize B-Iymphopoiesis (23). Bone
marrow and spleen preparations were isolated and negative cytolytic selection to
independently remove Ig+ cells, Ia+ cells and CR+ cells was performed (24-27). After
cytolysis of the Ig+ cells, induction resulted only in the formation of Ig+ cells. After
cytolysis of Ia+ cells, induction resulted in the formation of Ig+ and Ia+ cells. Finally,
induction of the cells remaining after cytolysis of CR+ cells resulted in the formation of Ig+,
Ia+ and CR+ cells. They therefore concluded, B-Iymphopoiesis proceeds from the most
primitive B cell progenitors that were Ig-, Ia-, CR- cells to Ig+, Ia-, CR- cells to Ig+, Ia+,
CR- cells to mature Ig+,Ia+,CR+ cells.
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Monoclonal antibodies and the characterization of B-Iymphopoiesis.
In an attempt to dissect the early stages of B-Iymphopoiesis, monoclonal antibodies
were utilized to examine the expression of the Qa antigen by primitive hemopoietic and
committed B-Iymphoid progenitors (31-33). Qa was found to be expressed by pluripotent
stem cells, granulocyte-macrophage progenitors and by B cells and their progenitors.
Therefore, Qa was ineffective for use in enrichment or isolation of B-Iymphoid precursors
because of its nonspecific pattern of expression. The monoclonal antibody 19B5 (34), was
found to bind hemopoietic cells in the marrow that were sensitive to infection by the
Ableson murine leukemia virus. Paige et al. demonstrated that 19B5 was expressed by the
earliest identifiable committed B-Iymphoid progenitors, and was not expressed by
multipotential stem cells (35). Later, monoclonal antibodies directed against the Lyb-l and
Lyb-2 antigens were found to be present on mature B cells and a small fraction of surface
Ig negative cells present in bone marrow (36, 37). However, these antigens although
expressed by B cells and their progenitors proved to have little usefulness due to their lack
of specificity for populations of committed B-Iymphoid progenitors.
In 1981 two monoclonal antibodies, 14.8 and RA3 3Al, were independently
isolated and characterized by Kincade et al. (22) and Coffman et aI., (21) respectively that
have revolutionized the study of B-Iymphopoiesis by surface Ig negative B-Iymphoid
progenitors. In the mid 1970's Trowbridge et aI. characterized the expression of a surface
glycoprotein with a molecular weight of approximately 220,000 daltons that was a member
of the T200 family of lymphoid glycoproteins that appeared to be specifically expressed by
cells of the B-Iymphoid lineage (38, 39). The T200 family of glycoproteins is composed
of 3 members with molecular weights of 170,000, 180,000 and 220,000 daltons (39). The
expression of the 220,000 dalton protein was restricted to B cells and their progenitors,
with the exception of a small population of activated T-Iymphocytes present in enlarged
lymph nodes (22, 41, 42). Coffman et al. proposed that this antigen be designated B220,
denoting its molecular weight and its specificity to the B-Iymphoid lineage (40). Further
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characterization of the B-Iymphoid progenitors positive for the expression of B220 revealed
the earliest B-Iymphoid progenitors expressing B220 were large Ig negative cells.
Populations of large and small cytoplasmic J.l chain positive pre-B cells and small B cells
were positive for the expression of B220 (22).
Having identified a B-Iymphoid specific marker, B220, Kincade staged the
expression of the antigens Qa, 19B5, 14.8 and surface Ig and characterized Blymphopoiesis and the progression from primitive multipotential cells to mature B cells
(43). Multipotential stem cells were characterized by their expression of Qa. The
expression of 19B5 by Qa positive cells marked commitment to the B-Iymphoid lineage.
Eventually Qa+ 19B5+ cells expressed B220. The B-Iymphoid progenitors positive for the
expression of B220 were subdivided into large Ig- pre-B cells, large cytoplasmic J..1+ pre-B
cells, small cytoplasmic J..1+ pre-B cells and small mature B cells (43).

Staging of B220+ surface Ig- B-Iymphoid progenitors
Hardy et al. pursued further characterization of B-Iymphopoiesis by making use of
multicolor flow cytometry to isolate specific populations of surface Ig negative B-Iymphoid
progenitors, based on their differential expression of CD43, HSA , BP-l (23, 44) and the
pan-B cell antigen B220. Upon obtaining a population of B220+ CD43+ cells, they
subdivided this population into 3 fractions: HSA- Bp-l-; HSA+ BP-l- and HSA + BP-l +.
The remaining population ofB220+ CD43- cells were found to be HSA+ and BP-l+. By
sorting, homogenous populations of each of the 4 fractions were obtained. Culture of
these homogenous populations in the presence of the ST2 stromal cell line and IL-7, alone
and in combination, revealed the progression of differentiation was most likely from B220+
CD43+ HSA - BP-I- to B220+ CD43+ HSA + BP-l- to B220+ CD43+ HSA + BP-I + to
B220+ CD43+ HSA+++ BP-l + ending with B220+ CD43- HSA+ BP-l +, and these stages
were designated A, B, C, C' and D respectively. With the isolation of such pure
populations of B-Iymphoid progenitors, the status of the Ig gene rearrangement of the
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progenitors present in each stage was determined. These studies revealed that the Ig genes
of cells in stage A were in germ line configuration, whereas 60% and 850/0 of the cells
present in stages B and C exhibited D-JH rearrangement respectively. It was not until stage
D that V rearrangements could be detected and 95% of these cells were positive for the DJH rearrangement. These studies reveal that, with sufficient enrichment, studies of the

molecular events of the various stages of B-Iymphopoiesis can be examined.
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IN VITRO B-LYMPHOPOIESIS.

To study the growth of pre-B cells infected with the Ableson murine leukemia virus

in vitro, Whitlock and Witte modified the long term Dexter culture for myelopoiesis (45,
46). Their modifications included, increasing the culture temperature from 33 to 37
degrees Celsius and eliminating the addition of corticosteroids, known to stimulate
granulopoiesis (47) while inhibiting several stages of B cell maturation (48). In their
studies they observed the growth of B cells and their progenitors in the uninfected control
cultures. Realizing the importance of this observation, they established a long term culture
assay capable of supporting the differentiation of B cells and their progenitors. In 1982
Whitlock and Witte demonstrated that their modified Dexter cultures were capable of
supporting extended in vitro B-Iymphopoiesis for more than 1 year (49). Briefly, the entire
marrow compartment of mice less than 4 weeks old was cultured at 37 degrees C in the
presence of low concentrations of horse serum, 2 mercaptoethanol (ME) and the absence of
corticosteroids. The cultured bone marrow cells proceeded through 4 distinct phases of
growth: 1) the proliferation of adherent cells to confluency that ends with a decrease in the
non adherent cells; 2) the crisis phase, in which the nonadherent cells decline; 3) the
proliferation of B-Iymphoid progenitors; and 4) the rapid proliferation of sub populations
of B-lineage cells (50).

Growth factor requirements of B-Iymphopoiesis.
The differentiation of the B-Iymphoid progenitors in the Whitlock-Witte culture
system required close association and interaction between the stromal cell elements and the
differentiating B-Iymphoid progenitors. Stromal cell layers established from crude bone
marrow preparations, as in the Whitlock-Witte system, are composed of adipocytes,
fibroblasts, endothelial cells and other formed marrow elements. Therefore, to more
completely define and understand the required interactions between individual types of
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stromal cells and B-Iymphoid progenitors, investigators isolated stromal cell lines that were
capable of supporting B-Iymphopoiesis or limited B-Iymphopoiesis (51-65).
While in search of soluble mediators capable of supporting the differentiation of Blymphoid progenitors, Namen et ale established the IxN/A6 cell line by transfecting bone
marrow stromal cell layers with SV40 (66). IxN/A6 secreted a substance that was capable
of supporting the differentiation ofB-lymphoid progenitors isolated from Whitlock-Witte
cultures. The factor secreted by IxNIA6, originally designated BP-l, synergistically
enhanced the proliferation of B-Iymphoid progenitors in serum-free cultures stimulated
with LPS. Later, in 1988 Namen et al. cloned the gene ofBP-l, purified the protein and
designated the product interleukin (lL) -7 (67). Further characterization of the role of IL-7
in support of B-Iymphopoiesis revealed that IL-7 was capable of supporting the
proliferation ofB220- and B220+ progenitors isolated from long term Whitlock-Witte
cultures.
As IL-7 was being characterized, the roles of the stromal cell clones ST2 (68) and
PA6 (69) in B-Iymphopoiesis were being examined. They demonstrated that ST2 was
capable of supporting the complete differentiation of the B-Iymphoid lineage. However,
PA6 was unable to support B-Iymphopoiesis by similar populations of B-Iymphoid
progenitors. In an attempt to determine if the PA6 stromal cell line was only permissive for
the expression of the myeloid lineage, transfer experiments were conducted (70). These
experiments revealed that PA6 was capable of supporting limited B-Iymphopoiesis.
Transfer of the arrested B-lymphoid progenitors to ST2 conditions permitted continued
differentiation. Therefore, they concluded that B-lymphopoiesis required the presence of at
least two major regulatory signals (70). Having been identified as a cytokine that supports
B-Iymphopoiesis by both B220- and B220+ progenitors, it was logical to wonder if IL-7
was the regulatory signal that the P A6 cell line was lacking. Addition of IL-7 to P A6
cultures generated permissive conditions for B-Iymphopoiesis, similar to the conditions of
the ST2 cultures (68, 69). These observations revealed that the most primitive B-Iymphoid
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progenitors required the presence of the P A6 factor to proliferate and differentiate, then the
combined interaction of P A6 factor and IL-7 was required, resulting in a progenitor that
was capable of proliferation in the presence of IL-7 alone (71, 72).
In 1990 Zsebo et aL cloned the ligand for the murine c-kit tyrosine kinase receptor.
This ligandlcytokine has been referred to as mast cell growth factor, stem cell growth
factor, the ligand for c-kit and Steel factor (73). In this manuscript I will refer to this ligand
as Steel factor (SF), as it is the factor that is deficient in the classically described Steel
mutant mice (74). In 1992 McNiece et al. examined the role of SF in B-Iymphopoiesis
(75). Interestingly, SF was found to synergize with IL-7 in support of the formation of
pre-B cell colonies by B220- B-Iymphoid progenitors from normal murine bone marrow in
agar culture.

The clonal identification of lymphohemopoietic progenitors from 5-FU treated mice.
Knowing that SF and IL-7 synergized in support of the proliferation and
differentiation of B220- B-Iymphoid progenitors in in vitro culture (75), Hirayama et al. in
1992 developed a culture assay capable of the clonal identification of lymphohemopoietic
progenitors in the absence of stromal cell support (76). In this assay, primitive
. hemopoietic progenitors from mice treated with 5 flurouracil were enriched by a
combination of density gradient centrifugation, negative immunomagnetic selection
removing committed cells expressing Mac~l, Gr-l, TERl19, L3T4, Lyt2, and B220 and
fluorescence activated cell sorting (77). Cells positive for the expression of the Ly 6AIE
(Sea-I) antigen (78) were sorted, and the cells present in this population were designated
Lin- Sca-l + cells. The enriched population of Lin- Sca-l + cells were cultured in the
presence of pokeweed mitogen spleen cell conditioned medium (PWM-SCM), SF, IL-7
and erythropoietin for 11 days. After 11 days of primary culture, the primary colonies
were individually harvested, washed and divided into two aliquots, one for replating in
myeloid suspension culture for identification of myeloid lineage expression and the other
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for replating in B-Iymphoid semisolid culture for identification of pre-B cell colonies.
Two, 4 and 6 days after the initiation of the secondary culture, the cytology of the myeloid
cells present in suspension culture was examined. The B-Iymphoid cultures were
examined for the presence of pre-B cell colonies after 12 days of secondary culture.
Additional investigations revealed that the purified cytokines IL-l1, IL-6 and G-CSF were
capable of replacing PWM-SCM with no deleterious effects.
Having laid the foundation of the modeling, characterization and in vitro culture of
B-Iymphopoiesis, the investigations conducted in pursuit of the hypothesis: "Commitment
to the individual myeloid and B-Iymphoid lineages occurs randomly as a single event rather
than as two events, commitment to myeloid and lymphoid lineage and later commitment of
the myeloid and lymphoid restricted progenitors to the individual myeloid and lymphoid
lineages." will be presented in the following chapters.
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Table 1-1. Definitions of commonly used terms
B-Iymphoid potential- gives rise to cells of the B-Iyrnphoid lineage.
B-Iymphoid progenitors- cells capable of giving rise to cells of the B-Iymphoid lineage.
B-Iymphopoiesis- the process of producing B-Iymphoid lineage cells.
Bipotential B-Iymphoid/macrophage progenitor- a cell capable of giving rise only to cells of
the B-Iymphoid and macrophage lineages.
Cell-cycle dormant- a progenitor that resides in the stage Go and is not engaged in
replication stages Gl, S, G2, or M of the cell cycle.
Clonal origin - derived from a single cell.
Colony fonning unit- a cell capable of giving rise to a colony.
Colony forming unit spleen CCFU-S)- a hemopoietic progenitor capable of seeding in the
spleen when transplanted into a lethally irradiated mouse, and forming a
macroscopic hemopoietic colony in the spleen.
Day 8 CFU-S- progenitors forming hemopoietic colonies in the spleen of recipient
mice 8 days after transplantation. A large majority of these progenitors are
sensitive to the cytotoxic effects of the chemotherapeutic drug 5-FU, and are
believed to be actively proliferating.
Day 12 CFU-S- progenitors forming hemopoietic colonies in the spleen of recipient
mice 12 days after transplantation. These progenitors are resistant to the
cytotoxic effects of 5-FU and are believed to be cell cycle dormant
progenitors.
Commitment- the process of lineage restriction.
Committed- restricted to a certain pathway of differentiation.
Conventional view of hemopoietic differentiation- a view of hemopoietic differentiation that
holds that hemopoietic stem cells reside in Go, and when they begin the process of
hemopoiesis, the myeloid and lymphoid lineage potentials quickly diverge giving
rise to myeloid and lymphoid restricted progenitors with limited self-renewal
capacity.
Differentiation- the process of becoming more mature.
Early actin2 triggering factor- a cytokine capable of triggering a cell cycle dormant
hemopoietic progenitor to begin proliferating.
Enriched progenitors- a population of progenitors that contains a relatively high incidence
of the progenitor of interest.
Flow cytometric analysis- examination of the antigen expression of a population of cells
using fluorescent labeled antibodies and a flow cytometer.
Flow cytometric sorting-the isolation of a specific population of cells based on their size,
internal structure and surface antigen expression using a fluorescence activated cell
sorter (FACS).
Hemopoiesis- the process of generating blood! hemopoietic cells of any or all lineages:
neutrophils, macrophages, mast cells, erythrocytes, megakaryocytes, B-Iymphoid
and T -lymphoid cells.
Hemopoietic progenitor- a cell capable of giving rise to blood cells.
In-situ- refers to the presence of a hemopoietic colony in the medium in which it developed,
i.e. methylcellulose.
Intermediate acting supportive factor- a cytokine which supports the survival and
differentiation of primitive hemopoietic progenitors actively proliferating.
Late acting proliferative factor- a cytokine which supports the most terminal stages of
differentiation of hemopoietic progenitors.
Lymphohemopoietic potential- the potential to give rise to cells of the myeloid and the
lymphoid lineages.
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Table 1-1. continued
Lymphohemopoietic progenitor- a cell capable of giving rise to cell of both the B-Iymphoid
and the myeloid lineages.
Lymphoid lineage- of or pertaining to B- and T lymphoid cells.
Lymphoid potential- having the ability to give rise to cells of both the B- and T-Iymphoid
lymphoid lineage
Lymphoid restricted progenitor- a progenitor with the capacity to give rise to cells of both
the B- and T-Iymphoid lineages.
Lymphomyeloid colony- a colony containing both B-Iymphoid and myeloid lineage cells.
Lymphopoiesis- the segment of hemopoiesis pertaining to the production of lymphoid
lineage cells.
Mature- a tenn that places the point of hemopoietic differentiation relatively closer to that of
being terminally differentiated.
Micromanipulation- the process of the harvest and placement of an individual cell under
direct microscopic visualization.
Myeloid lineage- of or pertaining to neutrophil, basophil, eosinophil, macrophage,
monocyte, erythroid, megakaryocyte cells.
Myeloid potential- having the ability to give rise to cells of the myeloid lineage.
Myeloid restricted progenitor- a cell whose lineage expression is restricted to that of the
myeloid lineage.
Myelopoiesis- the segment of hemopoiesis pertaining to the production of myeloid lineage
cells.
Non-synchronized population-A population of progenitors that contains individual
progenitors at varying stages of differentiation.
Pluripotent- having the ability to give rise to all blood cells: B-, T-Iymphoid and myeloid
lineage cells.
Pre-B cell- a B-Iymphoid progenitor that has cytoplasmic immunoglobulin mu chains
present in its cytoplasm and is positive for the expression of the B220 surface
antigen.
Pre-B cell cluster- an identifiable aggregate of pre-B cells that is present in a
lymphomyeloid colony.
Pre-B cell colony- a clonal colony of pre-B cells.
Primitive- a tenn that places the point of hemopoietic differentiation relatively closer to that
of hemopoietic stem cells.
Primitive hemopoietic progenitors- progenitors that are formed by stem cells and remain
very undifferentiated, having extensive proliferative and differentiative
capacity but limited self-renewal capacity.
Pro-B cell- a B-Iymphoid progenitor that gives rise to pre-B cells
Progenitor- a cell capable of giving rise to another cell.
Progeny- the resultant product of a cell division.
Proliferating - cells actively engaged in the cell cycle resulting in cell division.
Self-renewal- a cell division which gives rise to at least one daughter cell that is identical to
the parent, associated with no differentiation.
Spleen colony - a colony of hemopoietic cells of clonal origin present in the spleen of a
lethally irradiated mouse reconstituted with donor marrow.
Spleen colony assay- the first quantitative assay for the identification of primitive
hemopoietic progenitors which requires the lethal irradiation of a recipient mouse
followed by the transplantation of specific donor mouse hemopoietic progenitors,
and the subsequent harvest and examination of the recipient mouse spleen for
macroscopic hemopoietic colonies designated spleen colonies.
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Table 1-1. continued
Steel Factor (SF)- a cytokine/ligand that is the ligand for the c-kit receptor. This cytokine
in the past has been referred to as mast cell growth factor, stem cell factor and the
ligand for the c-kit receptor.
Stem cells- the most primitive of hemopoietic progenitors with myeloid and lymphoid
lineage potential and unlimited self-renewal potential.
Stochastic model of hemopoiesis- a model of hemopoiesis that holds the events governing
hemopoietic cell commitment and proliferation are based in randomness, and that
external factors are supportive and are not able to influence these processes.

Figure 1-1. The conventional view of hemopoietic differentiation. Only the most
primitive hemopoietic progenitors are believed to retain lymphoid and myeloid
potential. These progenitors are believed to give rise to common myeloid and
common lymphoid progenitors. These common progenitors are believed to
proliferate and result in the formation of the mature myeloid lineages: neutrophil, n;
macrophage, m; erythroid, E; megakaryocyte, M; mast cell, Mast; eosinophil, eo
and the lymphoid lineages B cells and T cells independently.

Pluripotent
Lymphohemopoietic
Progenitor

Common Myeloid
Progenitor

Common Lymphoid
Progenitor

/\
8 8
80.8
808

o

Figure 1-2. The progressive elucidation of the stages of B-Iymphopoiesis by lymphohemopoietic and committed B cell

progenitors.
In 1975 Miller et ale (16) using sedimentation velocity was able to identify 3 different populations of B cells and their
progenitors. PB cells give rise to B1 cells that give rise to B2 cells, in each case these cells were identified as expressing surface
Immunoglobulin. Miller, R. G. et al. Fed. Proc. 34; 145-150,1975.
In 1976 Hammerling et al. (17) characterized B cells and their precursors based on antigen expression. Ig, surface

immunoglobulin; la, immune response gene and CR, complement component, Hammerling, U. et ale PrDc. Natl. Acad. Sci.
USA. 73, 2008-2012, 1976.

In 1981 Kincade et al. (19) characterized B-Iymphopoiesis using monclonal antibodies Qa, 19B5 and B-Iymphoid specific
14.8 and the immunoglobulin expression of the progenitors at each stage, Kincade, P. W. et al. Adv. ImmunoL 31; 177-245,
1981.
In 1991 Hardy et al. (20) characterized the stages of B220+ slg- B-Iymphoid progenitors using CD43, HSA and BP-l.
Five stages of progenitors were identified based on thier antigen expression and the growth requirements and Ig gene
rearrangement status was determined, Hardy, R. R. et al. J. Exp. Med. 173; 1213-1225,1991.
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OUTLINE OF DISSERTATION

The work in this dissertation concentrates on the characterization of early Blymphohemopoiesis by lymphohemopoietic and early committed B-Iymphoid progenitors
following the establishment of an in vitro culture assay capable of supporting the clonal
differentiation of lymphohemopoietic progenitors isolated from 5-FU treated mice. The
content of Chapter II was published as "Ball, T. C., F. Hirayama, and M. Ogawa.
Lymphohematopoietic progenitors of normal mice. Blood. 85; 3086-3092, 1995." In this
chapter the establishment of the single-step assay for the identification of murine
lymphohemopoietic progenitors, and the characterization of the lymphohemopoietic
progenitors from normal mice is described. The content of Chapter III was published as
"Ball T. C., F. Hirayama, and M. Ogawa. Modulation of early B-Iymphopoiesis by
interleukin-3." Experimental Hematology. 24,1225-1231,1996. In this chapter 3 stages
of early B-Iymphopoiesis by lymphohemopoietic progenitors from 5-FU treated mice, and
the effect of IL-3 exposure on progenitors in each of these stages is described. The content
of Chapter IV remains unpublished. In this chapter I describe the expression of the Blymphoid and the myeloid lineages by enriched progenitors isolated from normal mice is
described, along with a modified version of a model of hemopoietic differentiation that
includes a random restriction of lineage potentials with a late divergence of the B-Iymphoid
lineage from possibly a bipotential B-Iymphoid/macrophage progenitor.

24

REFERENCES

1. Fabricius, H. "De formatione ovi et pulli tractatus accuratissimus." PataviL Ex
Officina Aloysij Bencij Bibliopolae. 1621.
2. Warner, N. L. and A. Szenberg. "The Immonological Function of the Bursa of
Fabricius in the Chicken." A. Rev. Microbiol. 18,253-265, 1964.
3. Riott, I. M., M. F. Greaves, G. Torrigiani, J. Brostoff, and J. H. L. Playfair. "The
Cellular Basis of Immunological Responses." The Lancet. 367-371, 1969.
4. Brahim, F., and D. G. Osmond. "The Migration of Lymphocytes from Bone Marrow
Labelling with H3_ thymidine In Vivo. Anat. Rec. 175, 737-746 1973.
5. Osmond, D. G. "Formation and Maturation of Bone Marrow Lymphocytes."

L

Reticuloendothel. Soc. 17; 99-105, 1975.
6. Osmond, D. G. "Proliferation Kinetics and the Lifespan ofB Cells in Central and
Peripheral Lymphoid Organs." Curro Opine Immuno!. 3; 179-185 , 1991.
7. Rolink, A. and F. Melchers. "B Lymphopoiesis in the Mouse." Adv.Immuno!. 53;
123-156, 1993.
8. Abramson, S., R. G. Miller, and R. A. Phillips. "The Identification in Adult Bone
Marrow of Pluripotent and Restricted Stem Cells of the Myeloid and Lymphoid Systems."
J. Exp. Med. 145; 1567-1579, 1977.
9. Ford, C. E., J. L. Hamerton, D. W. H. Barnes, and 1. F. Loutit. "Cytological
Identification of Radiation-Chemaeras." Nature. 177; 452-454, 1956.
10. Wu, A. M., J. E. Till, L. Siminovitch, and E. A. McCullough. "Cytological
Evidence for a Relationship Between Norman Hematopoietic Colony-Forming Cells and
Cells of the Lymphoid System." J. Exp. Med. 127; 455-463, 1967.
11. Dick, J. E., M. C. Magli, D. Huszar, R. A. Phillips, and A. Berstein. "Introduction
of a Selectable Gene into Primitive Stem Cells Capable of Long-Term Reconstitution of the
HemopoieticSystemofWIWMice." Cell. 42; 71-79,1985.

25

12. Keller, G., C. Paige, E. Gilboa, and E. F. Wagner. "Expression of a Foreign Gene
in Myeloid and Lymphoid Cells Derived from Multipotent Haematopoietic Precursors."
Nature. 318; 149-154.
13. Lemischka, I. R., D. H. Raulet, and R. C. Mulligan. "Developmental Potential and
Dynamic Behavior of Hematopoietic Stem Cells." Cell. 45; 917-927, 1986.
14. Harrison, D. E. "Competitive Repopulation: A New Assay for Long-Term Stem Cell
Functional Capacity." Blood. 55; 77-84, 1980.
15. Harrison, D. E.and R. K. Zhong. "The Same Exhaustible Multilineage Precursor
Produces both Myeloid and Lymphoid Cells as Early as 3-4 Weeks After Marrow
Transplantation." Proc. Nat!. Acad. Sci. USA. 89; 10134-10138, 1992.
16. Harrison D. E., C. T. Jordan, R. K. Zhong and C. M. Astle. "Primitive Hemopoietic
Stem cells: Direc Assay of Most Productive Populations by Competitive Repopulation with
simple binomial correlation and Covarience Calculations." Experimental Hematology. 21:
206-219, 1993.
17. Davidson, W. F., 1. H. Pierce, S. Rudikoff, and H. C. Morse III. "Relationships
Between B Cell and Myeloid Differentiation." 1. Exp. Med. 168; 389-487, 1988.
18. Cumano, A., C. 1. Paige, N. N. Iscove, and G. Brady. "Bipotential Precursors of B
Cells and Macrophages in Fetal Liver." Nature. 356; 612-615, 1992.
19. Miller, R. G. and R. A. Phillips. "Development of B Lymphocytes." Fed. Proc. 34;
145-150, 1975.
20. Hanunerling, V., A. F. Chin, and J. Abbott. "Ontogeny of Murine B Lymphocytes:
Sequence of B-ceU Differentiation from Surface-Immunoglobulin-Negative Precursors to
Plasma Cells." Proc. Nat!. Acad. Sci. USA. 73; 2008-2012, 1976.
21. Coffman, R. L., and I. L. Weissman. U'A Monoclonal Antibody that Recognizes B
Cells and B Cell Precursors in Mice." J. Exp. Med. 153; 269-279, 1981.
22. Kincade, P. W., G. Lee, T. Watanabe, L. Sun, and M. P. Scheid. "Antigens
Displayed on Murine B Lymphocyte Precursors." J.lmmunol.. 127; 2262-2268, 1981.

26

23. Hardy, R. R., C. E. Carmack, S. A. Shinton, J. D. Kemp, and K. Hayakawa.
"Resolution and Characterization of Pro-B and Pre-Pro-B Cell Stages in Normal Mouse
bone Marrow." J. Exp. Med. 173; 1213-1225, 1991.
24. Lafleur, L., R. G. Miller, and R. A. Phillips. "A Quantitative Assay for the
Progenitors of Bone Marrow-Associated Lymphocytes." J. Exp. Med. 135; 1363-1375,
1972.
25. Lafleur, L., R. G. Miller, and R. A. Phillips. "Restriction of specificity in the
Precursors of Bone Marrow-Associated Lymphocytes." J. Exp. Med. 137; 954-966,
1973.
26. Miller, R. G. and R. A. Phillips. "Development of B Lymphocytes." Fed. Proc. 34;
145-150, 1975.
27. Bianco, C., R. Patrick, V. Nussenzweig. "A Population of Lymphocytes Bearing a
Membrane Receptor for Antigen-Antibody-Complement Complexes. I. Separation and
Characterization." J. Exp. Med. 132; 702-720,1970.
28. Raff, M. C. "Two Distinct Populations of Peripheral Lymphocytes in Mice
Distinquishable by Immunofluorescence." Immunology. 19; 637-650, 1970.
29. David, C. S., D. C. Shreffler, and J. A. Frelinger. "New Lymphocyte Antigen
System (Lna) Controlled by the Ir Region of the Mouse H-2 Complex." Proc. Nat!. Acad.
Sci. USA. 70; 2509-2514, 1973.
30. Haupfeld, Y., D. Klein, and J. Klein. "Serologic detection of Antigens Controlled by
the Ir Region of the h-2 Complex in the Mouse." Science. 181; 167-169, 1973.
31. Flaherty, L., D. Zimmerman, and K. A. Sullivan. "Qa-2 and Qa-3 Antigens on
Lymphocyte Subpopulations. I. Mitogen Reponsiveness." J.Immuno!.

121; 1640-

1643, 1978.
32. Kastner, D. L., R. R. Rich, and F. W. Shen. "Qa-l-Associated Antigens. I.
Generation of H-2 Nonrestricted Cytotoxic T Lymphocytes Specific for Determinants of
the Qa-l Region." J. Immuno!. 123; 1239-1244, 1979.

27

33. Kincade, P. W., L. Flaherty, G. Lee, T. Watanabe, and J. Michaelson. "Qa
Antigen Expression on Functional Lymphoid, Myeloid, and Stem Cells in Adult Mice." L
Immuno!. 124; 2879-2885, 1980.
34. Shinefeld, L. A., V. L. Sato, and N. E. Rosenberg. "Monoclonal Rat anti-Mouse
Brain Antibody Detects Abelson Murine Leukemia Virus Target Cells in Mouse Bone
Marrow." CelL 20; 11-17, 1980.
35. Paige, C. J., P. W. Kincade, L. A. Shinefeld, and V. L. Sato. "Precursors of Murine

B Lymphocytes." J. Exp. Med. 153; 154-165,1981.
36. Sato, H. and E. A. Boyse. "A New Alloantigen Expressed Selectivly on B Cells: the
LyB-2 System." Immunogen. 3; 565-575, 1976.
37. McKenzie, I. F. C., and G. D. Snell. "Ly-4.2: a Cell Membrane Alloantigen of
Murine B Lymphocytes. I. Population Studies." J. Immunol. 114; 8-18, 1975.
38. Trowbridge, I. S., P. Ralph, and M. J. Bevan. "Differences in the Surface Proteins
of Mouse Band T Cells." Prec. Nat!. Acad. Sci. USA. 72; 157-161,1975.
39. Trowbridge, I. S., and C. Mazauskas. "Immunological Properties of Murine thymusDependent Lymphocyte Surface Glycoproteins." C. Bur. J. Immun. 6; 557-562, 1976.
40. Coffman, R. L., and I. L. Weissman. "B220: a B Cell-Specific Member of the T200
glycoprotien Family." Nature. 289; 681-683,1981.

41. Park, Y. H., and D. G. Osmond. "Phenotype and Proliferation of Earl B
Lymphocyte Precursor Cells in Mouse Bone Marrow." J. Exp. Med. 165; 444-458,
1987.
42.

Scheid~

M. P., K. S. Landreth, J. S. Tung, and P. W. Kincade. "Preferential but

Nonexclusive Expression of Macromolecular Antigens on B-Lineage Cells." ImmunoL
Rev. 69; 151-159, 1982.
43. Kincade, P. W. "Formation of B Lymphocytes in Fetal and Adult Life." In: Adv.
Immuno!. pages 177-245, 1981. Academic Press, 111 Fifth Avenue, New York, NY
10003.

28

44. Loffert, D., S. Schaal, A. Ehlich, R. R. Hardy, J. Zou, W. Muller, and K.
Rajewsky. "Early B~Cell Development in the Mouse: Insights from Mutations Introduced
by Gene Targeting." Immunol. Rev. 137, 135-151, 1994.
45. Dexter, T. M., and L. G. Lajtha. "Proliferation of Haemopoietic Stem Cells In Vitro."
Br. J. Haematol. 28; 525-530, 1974.
46. Whitlock, C. A., and O. N. Witte. "Abelson Virus-Infected Cells Can Exhibit
Restricted in Vitro Growth and Low Oncogenic Potential." J. Viral. 40; 577-584, 1981.
47. Greenberger, J. S. "Sensitivity of Corticosteroid-Dependent Insulin-Resistant
Lipogenesis in Marrow preadipocytes of Obese Diabetic (ab/db) Mice." Nature. 275;
752-754, 1978.
48. Baxter, J. D., and A. W. Harris. "Mechanism of Glucocorticoid Action: General
Features, with Reference to Steroid-Mediated Immunosuppression." Transpl. Proc. 7; 5565, 1975.
49. Whitlock, C. A. and o. N. Witte. "Long-term Culture of B Lymphocytes and Their
Precursors from Murine Bone Marrow." Proc. Nat!. Acad. Sci. USA. 79; 3608-3612,
1982.
50. Whitlock, C. A., D. Robertson, and O. N. Witte. "Murine B Cell Lymphopoiesis in
Long Tenn Culture." J. Immunol. Meth. 16; 353-369, 1984.
51. Zipori, D., D. Duksin, M. Tamir, A. Argaman, J. Toledo, and Z. Malik. "Cultured
Mouse Marrow Stromal Cell Lines. II. Distinct Subtypes Differing in Morphology,
Collagen Types, Myelopoietic Factors, and Leukemic Cell Growth Modulating activities."
J. Cell. Physiol. 122; 81-90, 1985.
52. Song, Z. X., R.K. Shadduck, D. J. Innes, A. Wadheed, and P. J. Quesenberry.
"Hematopoietic Factor Production by a Cell Line (TC-l) Derived from Adherent Murine
Marrow Cells." Blood. 66; 273-281, 1985.

29

53. Li, C. L., and G. R. Johnson. "Stimulation of Multipotential, Erythroid and Other
Murine Haematopoietic Progenitor Cells by Adherent Cell Lines in the Absence of
detectable Multi-CSF (IL-3)." Nature. 316; 633-636, 1985.
54. Whitlock, C. A., G. F. Tidmarsh, C. Muller-Sieburg, and I. L. Weissman. "Bone
Marrow Stromal Cell Lines with Lymphopoietic Activity Express High Levels of a Pre-B
Neoplasia-Associated Molecule." Cell. 48; 1009-1021, 1987.
55. Li, C. L., R. L. Culter, and G. R. Johnson. "Characterization of Hemopoietic
Activities in Media Conditioned by a Murine Marrow-Derived Adherent Cell Line, B. Ad."
Exp. Hematol. 15; 373-381,1987.
56. Quesenberry, P., Z. X. Song, E. McGrath, I. McNiece, R. Shadduck, A. Waheed,
G. Baber, E. Kleeman, and D. Kaiser. "Multilineage Synergistic Activity Produced by a
Murine Adherent Marrow Cell Line." Blood. 69; 827-835, 1987.
57. Collins, L. S., and K. Dorshkind. "A Stromal Cell Line from Myeloid Longterm
bone Marrow Cultures Can Support Myelopoiesis and B Lymphopoiesis." J. Immunol.
138; 1082-1087, 1987.
58. Hunt, P., D. Robertson, D. Weiss, D. Rennick, F. Lee, and O. N. Witte. "A single
Bone Marrow-Derived Stromal Cell Type Supports the In Vitro Growth of Early Lymphoid
and Myeloid Cells." Cell. 48; 997-1007, 1987.
59. Rennick, D., G. Yang, C. Muller-Sieburg, C. Smith, N. Arai, Y. Takabe, and L.
Gemmell. "Interleukin 4 (B-cell Stimulatory factor 1) Can Enhance of Antagonize the
Factor.. Dependent Growth of Hemopoietic Progenitor." Proc. Natl. Acad. Sci. USA. 84;
6889-6893, 1987.
60. Leung, L. C., and C. R. Johnson. "In Vitro Maintenance of Hemopoieic Stem Cells
with Lymphoid and Myeloid Repopulating Ability by a Cloned Murine Adherent Bone
Marrow Cell Line." Exp. Remato!. 15; 989-994, 1987.

30

61. Pietrangeli, C. E., Sk. I. Hayashi, and P. W. Kincaide. "Stromal Cell Lines which
Support Lymphocyte growth: Characterization, Sensitivity to Radiation and
Responsiveness to Growth Factors." Eur. J. Immunol. 18; 863-872, 1988.
62. Landreth, K. S., and K. Dorshkind. "Pre-B Cell Generation Potentiated by Soluble
Factors from a Bone Marrow Stromal Cell Line." J. Immunol. 140; 845-852, 1988
63. Lowenthal, J. W., B. E. Castle, J. Christiansen, J. Schreurs, D. Rennick, N. Arai, P.

Hoy, Y. Takebe, and M. Howard. "Expression of High Affinity Receptors for Murine
Interleukin 4 (BSF-l) on Hemopoietic and Non-Hemopoietic Cells." J.Immunol. 140;
456-464, 1988.
64. King, A. G., K. S. Landreth, and D. Wierda. " Bone Marow Stromal Cell
Regulation of B-Lymphopoiesis: 1. The Role of Macrophages, Interleukin-1., and
Interleukin-4 in Pre-B Cell Maturation." J. Irnmunol. In press.
65. Kincade, P. W., G. Lee, C. E. Pietrangeli, S. I. Hayashi, and J. M. Gimble. "Cells
and Molecules that Regulate B Lymphopoiesis in Bone Marrow." Ann. Rev. Immunol.

7; 111-143, 1989.
66. Namen, A. E., A. E. Schmierer, C. J. March, R. W. Overell, L. S. Park, D. L.
Vrdal, and D. Y. Mochizuki. "B Cell Precursor Growth-Promoting Activity." J. Exp.

Merl. 167; 988-1003, 1988.
67. Namen, A. E., S. Lupton, K. Hjerrild, J. Wignall, D. Y. Mochizuki, A. Shmierer, B.
Mosley, C. J. March, D. Vrdal, S. Gillis, D. Cosman, and R. G. Goodwin. "Stimulation
ofB-Cell Progenitors by Cloned Murined Interleukin-7." Nature. 333; 571-573, 1988.
68. Ogawa, M., S. Nishikawa, K. Ikuta, F. Yamamura, M. Naito, K. Takahashi, and S.
Nishikawa. "B Cell Ontogeny in Murine Embryo Studied by a Culture System with the
Monolayer of a Stromal Cell Clone, ST2: B Cell Progenitor Develops First in the
Embryonal Body Rather that in the Yolk Sac." E.M.B.O. J. 7; 1337-1343, 1988.

31

69. Kodama, H., H. Sudo, H. Koyama, S. Kasai, and S. Yamamoto. "In Vitro
Hemopoiesis Wighin a Microenvironment Created by MC3T3-G2IPA6 Preadipocytes."

L

Cell. Phyiol.. 118; 233-240, 1984.
70. Nishikawa, S., M. Ogawa, S. Nishikawa, T. Kunisada, H. Kodama. "B
Lymphopoiesis on Stromal Cell Clone: Stromal Cell Clones Acting on Different Stages of
B Cell Diffentitaion." Eur. J. Immunol. 18; 1767-1771,1988.
71. Sudo, T., M. Ito, Y. Ogawa, M. Izuka, H. Kodama, T. Kunisada, S. Hayashi, M.
Ogawa, K. Sakai, S. Nishikawa, and S. Nishikawa. "Interleukin 7 Production and
Function in Stromal Cell-Dependent B Cell Development." J. Exp. Med. 170; 333-338,
1989.
72. Hayashi, S., T. Kunisada, M. Ogawa, T. Sudo, H. Kodama, T. Suda, S. Nishikawa,
and S. Nishikawa. "Stepwise Progression of B Lineage Diffeentiation Supported by
Interleukin 7 and Other Stromal Cell Molecules." J. Exp. Med. 171; 16830-1695, 1990.
73. Zsebo, K. M., D. A. Williams, E. N. Geissier, V. C. Broudy, F. H. Martin, H. L.
Atkins, R. Y. Hsu, N. C. Birkett, K. H. Okino, D. C. Murdock, F. W. Jacobsen, K. E.
Langley, K. A. Smith, T. Takeishi, B. M. Cattanach, S. J. Galli, and S. V. Suggs.
"Stern Cell Factor is Encoded at the SL Locus of the Mouse and Is the Ligand for the c-kit
Tyrosine Kinase Receptor." Cell. 63; 213-224, 1990.
74. Sarvella, P. A. and L. B. Russel. "Steel, a new dominant gene in the house mouse."

J. of Heredity. 47; 123-128, 1956.
75. McNiece, I. K., K. E. Langley,and K. M. Zsebo. "The Role of Recombinant Stem
Cell Factor in Early B Cell Development." J.lmmunol. 146; 3785-3790, 1991.
76. Hirayama, F., J. P. Shih, A. Awgulewitsch, G. W. Warr, S. C. Clark, and M.
Ogawa. "Clonal Proliferation of Murine Lymphohemopoietic Progenitors in Culture."
Proc. Nat!. Acad. Sci. USA. 89; 5907-11, 1992.
77. Shih, J. P., H. Q. Zeng, and M. Ogawa. "Enrichment of Murine Marrow Cells for
Progenitors of Multilineage Hemopoietic Colonies." Leukemia. 6; 193-8, 1991.

32

78. Spangrude, G. J., S. Heimfeld, and I. L. Weissman. "Purification and
Characterization of Mouse Hematopoietic Stem Cells." Science. 241; 58-62, 1988.

Chapter II
Lymphohemopoietic Progenitors of Normal Mice
Timothy C. Ball, Fumiya Hirayama and Makio Ogawa

34

INTRODUCTION

A two-step methylcellulose culture assay for murine lymphohemopoietic

progenitors capable of producing cells in B-cell and myeloid lineages was recently
developed in Dr. Ogawa's laboratory (1). In this system, enriched bone marrow cells of 5FU-treated mice were plated in the primary culture and the resulting colonies were analyzed
in secondary cultures containing steel factor (SF, ligand for c-kit) and interleukin (IL )-7 for
pre-B cell col~ny formation. SF plus IL-6, IL-l1, granulocyte-colony stimulating factor
(G-CSF) (7) or IL-12 (2) supported the differentiation and proliferation of B-cell
progenitors in the primary colonies. IL-3 failed to support B-Iymphopoiesis either alone or
in combination with other factors. Furthermore, when added to permissive culture
conditions, IL-3 and IL-l independently inhibited the B-cell potential of the primary
colonies (3). According to this culture assay, approximately 40% of the progenitors in the
lineage-negative (Lin-) Ly-6A/E (Sca-l)+ popUlation isolated from 5-FU-treated mice were
lymphohemopoietic in nature (1).
The chemotherapeutic drug 5-FU kills actively proliferating cells while sparing cell
cycle-dormant primitive hemopoietic progenitors. 5-FU has at least three mechanisms of
action, the first and probably most important is the irreversible inhibition of thymidylate
synthase which results in the depletion of thymidylate pools and the inhibition of DNA
synthesis. The second and third mechanisms involve the dIrect incorporation into DNA
and RNA, creating unstable molecules that lead to cell death as is discussed by Mini et al.
(4). It is possible that some of the cell cycling, maturer progenitors present in normal mice
may also possess lymphohemopoietic potential, and that the cytokine requirement of the
cycling lymphohemopoietic progenitors may be different from that of the progenitors in 5FU-treated mice. While the two-step culture assay may be suited for the synchronized
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population of cell cycle-dormant progenitors in the marrow of 5-FU-treated mice, it may
not be adequate for the progenitors present in normal mice since the latter are not
synchronized and represent varying stages of development. Replating on a fixed day of
incubation may significantly underestimate the number of progenitors. To address this
problem, I have developed a single-step methylcellulose culture assay and examined the
lymphohemopoietic progenitors in nonnal mice. My observations indicate that there are
more lymphohemopoietic progenitors in the bone marrow of normal mice than in the
marrow of 5-FU-treated mice.
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MATERIALS AND METHODS

Growth factors.
Conditioned medium (CM) of Chinese hamster ovary (CHO) cells transfected with
an expression plasmid containing murine SF cDNA was provided by Dr. D. Donaldson
(Genetics Institute Inc., Cambridge, MA). Purified recombinant human IL-7 was provided
by Dr. C. Faltynek (Sterling Drug Inc., Malvern, PA). Medium conditioned by eRG cells

genetically engineered to produce murine IL-3 at a high titer (-70,000 U/ml) was a gift from
Dr. T. Sudo (Biomaterial Research Institute, Yokohama, Japan). Purified bacteriallyderived human G-CSF was provided by Dr. L. Sousa (Amgen, Thousand Oaks, CA).
Purified recombinant human IL-II was provided by Dr. P. Schendel and IL-12 by Dr. S.
F. Wolf (Genetics Institute). Purified recombinant human IL-Iex was provided by Dr. Y.
Hirai, (Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan). Purified human
erythropoietin (Ep) was provided by the Genetics Institute Clinical Manufacturing Group.
Serum-free conditioned medium from pokeweed mitogen-stimulated spleen cells (PWMSCM) was prepared as described previously (5).

Monoclonal antibodies (mAbs).
Hybridoma D7 (anti-Ly-6A.21E.1, rat IgG 2a) was kindly provided by Dr. Paul
Kincade of Oklahoma Medical Research Foundation (Oklahoma City, OK). Hybridoma
14.8 (anti-B220, rat IgG2b), and Ml/70.15.11.5.HL (anti-Mae-I, rat IgG2b) were
obtained from the American Type Culture Collection (Rockville, MD). These antibodies
were purified from the culture supernatants by affinity chromatography on a Protein G
Sepharose 4 Fast Flow column (Pharmacia LKB Biotechnology, Piscataway, NJ).
TER 119 (anti ~erythrocyte mAb) was provided by Dr. T. Kina (Department of
Immunology, Chest Disease Research Institute, Kyoto University, Kyoto Japan). Biotinconjugated RB6-8C5 (anti-Gr-I, rat IgG2b) was purchased from PharMingen (San Diego,
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CA). Affinity-purified FITC-Iabeled goat-anti-rat IgG was purchased from Kirkegaard &
Perry Laboratories Inc. (Gaithersburg, MD). Anti-Mac-l and TER119 were conjugated in
our laboratory with biotin purchased from Vector Laboratories (Burlingame, CA). Rat IgG
was purchased from Zymed Laboratories (San Francisco, CA). Biotin-conjugated rat
IgG2b was purchased from Caltag Laboratories (San Francisco, CA). Streptavidinconjugated phycoerythrin (PE) was purchased from Jackson Laboratories (West Grove,
PA). Propidium iodide (PI) was purchased from Sigma Chemical Company (St. Louis,
MO) and used at a final concentration of 10 ug/ml.

Purification of progenitor cells.
Bone marrow cells were harvested from the femora and tibiae of 10 to 16 week-old
normal BDF! mice (Charles River, Raleigh, NC) and from mice 2 days after Lv. injection
of 5-FU (Adria Laboratories, Columbus OH) at 150 mg/kg (body weight). Cells were
enriched by a combination of density gradient separation, depletion of lineage marker
positive cells and positive sorting for the presence of the Ly-6NE antigen (6) as described
previously (7).

Methylcellulose culture of enriched progenitors from normal mice.
Fifty to 60 enriched normal marrow cells were plated in a 35 mm suspension
culture dish (Becton Dickinson Labware, Lincoln Park, NJ) containing a-medium (leN,
Irvine, CA), 1.2% (1500 centipoises) methylcellulose (Shinetsu Chemical Co., Tokyo,
Japan), 30% fetal calf serum (Intergen, Purchase, NY), 1% deionized fraction V bovine
serum albumin (BSA, Sigma Chemical Co.), 1 xl0-4M mercaptoethanol (ME, Eastman
Organic Chemicals, Rochester, NY), 2 U/rnl Ep and designated combinations of growth
factors. Dishes were incubated at 37 degrees C in a humidified atmosphere flushed with
5% CO 2 - In some experiments, enriched progenitors were individually plated by
micromanipulation in methylcellulose cultures as described previously (8). Unless specified
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otherwise, the concentrations of cytokines used here are as follows: SF CHO-CM, 5 U/ml;
IL-1a, 10 ng/ml; IL-3 CHO-CM, 200 V/ml; IL-7, 5 ng/ml; IL-1l, 100 ng/ml; IL-12, 10
ng/ml; Ep, 2 Vlml; G-CSF, 1 ng/ml and PWM-SCM, 5%.

Flow cytometric analysis of the B-cell potentials of individual colonies.
On day 16 and 17 of culture, after in situ examination of the types of colonies on an
inverted microscope, all colonies except small granulocyte-macrophage (GM) and
macrophage (M) colonies were harvested for analysis of B220+ cells. Bone marrow cells
of a nonnal mouse were used as control cells. Samples were first incubated with rat-antimouse B220 and then with goat-anti-rat IgG-FITC. Polyclonal rat IgG was added to block
the free binding sites of the goat-anti-rat IgG-FITC molecules. The samples were then
incubated with a cocktail of biotin-conjugated rat-anti-mouse mAb's consisting of anti-Mac1, anti-Gr-l, and TER 119 followed by streptavidin-PE. Finally, the samples were
incubated with propidium iodide (PI) at a concentration of 10 ug/ml. The cells from
individual colonies were analyzed by flow cytometry using a FACStar Plus flow cytometer
(Becton Dickinson, San Jose, CA) for the presence of B220+, Mac-l-, Gr-1-, TER119and PI- cells.

Two-step methylcellulose culture assay for lymphohemopoietic progenitors.
Enriched marrow cells from 5-FU-treated mice were assayed for
lymphohemopoietic progenitors by using the two-step culture assay as described
previously (7). Briefly, cells were plated in methylcellulose culture containing SF, IL-7,
Ep and IL-11 for 11 days, at which time individual colonies were lifted from the medium
with a micropipet. The colonies were washed and divided into two aliquots; two-thirds
were stained with a polychrome stain to examine myeloid cell morphology and one-third
was replated in methylcellulose culture containing SF and IL-7. Twelve days after
replating, the lymphoid cultures were examined for the presence of pre-B cell colonies (1,
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9). Enriched progenitors from normal mice were cultured in the presence of identical
cytokine mixtures. However, the optimal day for replating of the primary colonies to
observe maximal B-Iymphoid expression was determined to be day 8.

Analysis of myeloid lineage potentials of lymphohemopoietic progenitors.
Enriched progenitors from normal mice were individually micromanipulated into
methylcellulose medium containing SF, IL-7, Ep and IL-l1, and primary colonies were
allowed to develop. On day 11 of culture, one half of each colony present was lifted from
the medium and was transferred into 200 ul of myeloid specific culture medium containing
a-medium, 30% FCS, 1% BSA, 1 x 10-4 M 2ME, 5% PWM-SCM, 200 Vlml IL-3 and 2
U/ml Ep in a 96 well flat bottom tissue culture plate (Costar, Cambridge, MA). On day 4 of

secondary culture myeloid lineage expression was examined with May-Grunwald Giemsa
staining of cytospin preparations. The portion of each colony remaining in the initial
semisolid culture was harvested on day 19 of culture and analyzed by flow cytometry to
identify B220+, Mac-l-, Gr-l-, TERlI9- and PI- cells.

40

RESULTS

Identification of lymphohemopoietic colonies by flow cytometry.
When the enriched bone marrow cells from normal mice were cultured in the
presence of SF, IL-7, Ep and IL-ll for 16 days, some lymphomyeloid colonies were
easily identifiable in situ by their characteristic appearance. These colonies had the
appearance of multilineage myeloid colonies revealing red color of hemoglobin while also
presenting a few clumps of small round cells characteristic of pre-B cell colonies. A
photomicrograph of a representative colony is presented in Fig. 2-1. In addition, there were
pure pre-B cell colonies and clusters with the morphology described previously (1, 9) and
large multilineage myeloid colonies without an apparent B-cell component. However, the
majority of the growth seen in culture consisted of small OM and M colonies containing
fewer than 2,000 cells. In order to more accurately identify the colonies expressing a Blymphoid component, I carried out flow cytometric analysis of individual colonies for
identification of B220+ cells.
First, I established the sensitivity and specificity of the assay using a mixing
experiment. In this experiment, 105 cells from myeloid colonies known to lack pre-B cells
and varying numbers of pre-B cells from pooled pre-B cell colonies were combined and
subjected to flow cytometric analysis. The former population was obtained by culture of
enriched post-5-FU marrow cells for 14 days in the presence of SF, IL-7, Ep, IL-ll and
IL-3 (3) and the latter from day 11 primary colonies derived from enriched post-5-FU
marrow cells recultured in the presence of SF and IL-7 (1, 9). Using LYSIS II software,
forward and side scatter gates were set to include cells present in the lymphoid window
(10) and fluorescence gates were activated to include B220+, Mac-l-, Or-l-, TERl19- and
PI- cells. Routinely 4,000 events were collected for examination of individual colonies. The
results of this experiment are presented in Fig. 2-2A. As can be seen, the number of B220+
events is directly proportional to the percentage of pre-B cells present in an individual
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sample. Furthermore, I determined the threshold sensitivity, the minimum percentage of
pre-B cells that must be present in an individual colony to be identified to be 5%. In
activation of the lymphoid and fluorescence windows, acquired debris and PI positive
events are excluded, accounting for the discrepancy between the number of events acquired
and the number of events reported in the 100% pre-B cell sample of Fig. 2-2A. The flow
cytometric analyses of the B-Mix colony seen in Fig. 2-1. are shown in Fig. 2-2B. The
colony was lifted from the medium and divided into two aliquots. One was stained with the
myeloid mAb cocktail and rat IgG (C) and the other stained with the myeloid mAb cocktail
and the anti-B220 mAb (E). As can readily be seen, the colony contained many B220+ pre-

B cells.
Comparison of in situ morphological identification and analysis by use of flow
cytometry of individual colonies soon led to the conclusion that the latter method, flow
cytometry, was superior to the former, morphology, in identification of the B-Iymphoid
component. Results of three such comparisons are shown in Table 2-1. There was
excellent concordance between in situ microscopic examination and flow cytometric
analysis in the identification of pure pre-B cell colonies and B-Mix colonies, multilineage
myeloid colonies revealing typical pre-B cell colonies and clusters. However, a significant
number of apparent myeloid-restricted multilineage colonies (Mix colonies) revealed the
presence of a B-cell component upon flow cytometric analysis. As stated in the Materials
and Methods section, the GM and M colonies contained fewer than 2,000 cells and could
not be individually analyzed by flow cytometry. When all 77 of the GM and M colonies in
experiment 1, Table 2-1 were pooled and examined for B220+ cells by flow cytometry, no
pre-B cells were identified. Based on these observations, I established a single stage culture
for the identification of lymphohemopoietic colonies from normal mice in which all
colonies except small GM and M colonies were analyzed for B220+ cells by flow
cytometry.
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Clonality of the lymphomyeloid colonies identified by the single-step assay.
To establish single cell origin of the lymphomyeloid colonies, I carried out
micromanipulation of individual progenitor cells into semisolid culture. In experiment 1 of
Table 2-2, a total of 90 Lin- Sca. 1+ cells were micromanipulated into cultures containing
SF, IL-7 and Ep. Twenty-two colonies developed by day 16 of culture revealing a 240/0
plating efficiency. Seventeen of the colonies were small GM and M colonies and were not
analyzable by flow cytometry, while 5 of the colonies were harvested for analysis. One of
the colonies was a lymphomyeloid colony and 4 were pre-B cell colonies. In experiments 2
and 3 a total of 98 Lin- Sca-l + cells were micromanipulated into cultures containing SF, IL7, Ep and IL-11. The plating efficiency was 32% and a total of seven lymphomyeloid
colonies were identified. These results clearly established the clonal origin of the
lymphomyeloid colonies.

Cytokine requirements of lymphohemopoietic progenitors.
I next examined the minimal cytokine combinations required for formation of
lymphomyeloid colonies from enriched normal bone marrow cells. The results of this
examination are shown in Table 2-3. The combination of SF and Ep supported the
development of only myeloid colonies, a majority of which were small GM and M
colonies. IL-7 plus Ep supported formation of few GM and M colonies but failed to
support formation of pre-B cell colonies. The combination of SF, IL-7 and Ep supported
fonnation of not only GM and M colonies, but also pre-B cell colonies and
lymphomyeloid colonies. The numbers of GM and M colonies supported by the
combination of SF, IL-7 and Ep were similar to those supported by SF plus Ep.

Effects of Early-Acting Cytokines.
Earlier, several cytokines were identified which appear to act synergistically to
shorten the Go period of primitive progenitors and to support the proliferation of
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lymphohemopoietic progenitors of 5-FU-treated mice (11). I tested these early-acting
cytokines for possible synergistic effects on colony formation by normal marrow cells
supported by SF, IL-7, plus Ep. The results are presented in Table 2-4, experiment 1.
Again, the combination of SF, IL-7 and Ep supported lymphomyeloid and lymphoid
colony formation from normal marrow cells. Addition of IL-11, G-CSF or IL-12 to the
combination of SF, IL-7 and Ep greatly increased the numbers of all types of colonies
primarily lymphomyeloid, myeloid and small GM and M colonies. IL-12 exhibited the least
activity and the colonies developing in the presence of IL-12 were smaller than the colonies
developing in the presence of either IL-l1 or G-CSF as reported previously with post 5-FU
marrow cells (2).
It has been reported IL-3 and IL-la independently act as potent negative regulators
of the early stages of B-Iymphopoiesis using enriched marrow cells of 5-FU-treated mice
(3). In the next experiment I studied the effects of these cytokines on lymphomyeloid
colony fonnation from nonnal marrow cells. Results of two separate experiments are

presented in experiments 2 and 3 of Table 2-4. As can readily be seen, IL-3 and IL-la
independently suppressed the development of lymphomyeloid colonies and totally
abrogated formation of pre-B cell colonies.

Incidence of lymphohemopoietic progenitors in normal and 5-FU treated mice.
It was of interest to compare the incidence of lymphohemopoietic progenitors
present in normal mice with that in mice injected with 5-FU. To obtain a more valid result,
the single-step and the two-step assays were compared using progenitors from normal
marrow. It was however, impossible to assay progenitors from 5-FU-treated mice using
the single-step assay because of the proliferative capacity of the cells and the kinetics of Blymphoid expression. Approximately 21 days of culture were required before any Blymphoid lineage expression was detectable by FACS analysis at which time a majority of
the colonies had diameters greater than 2 mm and were rapidly degenerating. Marrow cells
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were harvested from two femora and two tibiae of each animal. The means and standard
deviations of four individual experiments conducted in each group are presented in Table 25. The numbers of lymphohemopoietic progenitors in the two femora and two tibiae of a
normal mouse estimated by the single-step and the two-step assay were 3,400 + 600 and
4,700 + 2,200, respectively and did not differ significantly. In contrast, the total number
of lymphohemopoietic progenitors in a 5-FU-treated mouse identifiable by the two-step
assay, was approximately one-fourth that of a normal mouse.
Further, the single-step and the two-step assays identified 5 + 2 and 5 + 1 percent
of the colonies from a normal mouse as B-Iymphoid, respectively, whereas no B-lymphoid
colonies were identified from the progenitors from 5-FU-treated mice.

Examination of the myeloid linea~e potentials of individual progenitors of normal mice.
A total of 49 Lin- Sca-l + cells isolated from normal mice were individually
micromanipulated into methylcellulose cultures containing SF, IL-7, Ep and IL-II. Fifteen
of the 49 cells gave rise to colonies on day 11 of culture, 2 of which were degenerated and
not suitable to evaluate. Four of the primary colonies gave rise to cells of both the myeloid
and the B-Iymphoid lineages. Results of cytochemical analyses of the cells are presented in
Table 2-6. While the number of colonies examined is small, there appears to be no
significant difference in the myeloid potentials of colonies regardless of the presence or
absence of B-Iymphoid potential.
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DISCUSSION

The development of an assay capable of the clonal identification of
lymphohemopoietic progenitors under defined culture conditions has proven useful in the
study of the mechanisms of early B- lymphopoiesis. Already, this assay has led to
characterization of the cytokine requirements of early B-Iymphopoiesis in vitro and
identification of possible negative modulatory roles of the cytokines IL-I a and IL-3 on
early B-Iymphopoiesis (2-3). I have now modified the two-step culture assay for the
progenitors in 5-FU-treated mice to develop a single-step clonal culture assay capable of
supporting the differentiation and proliferation of lymphohemopoietic progenitors of

nonnal mice.
My studies resulted in the identification of a significant number of progenitors
capable of giving rise to both B-Iymphoid and myeloid lineages. My calculation indicates
that approximately 4 times more lymphohemopoietic progenitors are present in the bone
marrow of a normal mouse than in a 5-FU-treated mouse. Recently, Lepault et al. (12)
examined the T- and B-Iymphoid potential of spleen-colony forming units (CFU-S), and
observed that the majority of day-8 CFU-S and almost all of day-12 CFU-S have T- and Blymphoid potentials. My observations in culture corroborate those of Lepault et al. in vivo
and suggest that many lymphohemopoietic progenitors are present in the normal mice, and
that a significant population of the progenitors is sensitive to the cytotoxic effects of 5-FU.
For the most part, the responses of the majority of lymphohemopoietic progenitors
isolated from normal mice to synergistic cytokines (IL-II, IL-I2 and G-CSF) and
inhibitory cytokines (IL-In and IL-3) are similar to those isolated from 5-FU treated mice.
However, a small number of progenitors of normal mice required only SF, IL-7 and Ep to
form lymphomyeloid colonies. The lack of this requirement for a additional synergistic
factors by some of the lymphohemopoietic progenitors of normal mice may suggest these
progenitors are actively proliferating. The single-step assay for lymphohemopoietic
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progenitors of nonnal mice will be useful in the study of commitment of
lymphohemopoietic progenitors.
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Table 2-1.

Comparison of in situ Colony Identification with Detection by Flow
Cytometry

Number of Colonies

B-Mix

Pre-B cell

Mix

Exp 1

18 (18)

11 (11)

27 (3)

77

Exp2

10 (10)

11 (11)

16 (1)

32

Exp3

19 (18)

8 (7)

23 (2)

31

GMIM

The numbers indicate colonies diagnosed in situ on an inverted microscope. The numbers
in the bracket indicate colonies revealing B220+ cells by flow cytometry. Lin- Sca-l + cells
of normal mice were cultured in the presence of SF, IL-7, Ep and IL-11. B-Mix,
multiline age colonies revealing B-Iymphoid clusters in situ; Pre-B Cell, Pre-B cell colonies
and clusters; Mix, multilineage myeloid colonies ostensibly lacking B-Iymphoid element.

Table 2-2.

Clonal Origin of the Lymphohemopoietic Colonies of Normal Mice

----Numbe! of Colonies
----...

Number

Analyzed by Flow Cytometry

of cells
Exp

Growth factors

plated

----0

Lympbomyeloid Lympl1 id

Small
Myeloid

GMIM

Total

"..--....

1

SF, IL-7, Ep

90

1

4

0

17

22

2

SF, IL-7, Ep, IL-11

49

3

1

2

10

16

3

SF, IL-7, Ep, IL-l1

49

4

1

3

7

15

.--....

Colonies were examined on day 16 or 17 of culture.

~
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Table 2 .. 3.

Minimum Cytokine Requirements of Lymphohemopoietic Progenitors

Colonies/ 2 dishes
Analyzed by Flow Cytometry
Small
Growth factors

Lymphomyeloid

Lymphoid

Myeloid

GM/M

Total

None

0

0

0

0

0

Ep

0

0

0

0

0

IL-7, Ep

0

0

0

3

3

SF,Ep

0

0

4

24

28

SF, IL-7, Ep

4

8

2

26
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Lin- Sca-l + cells of normal mice were plated in cultures at a concentration of 60 cells per
dish. Colonies were diagnosed in situ and analyzed by flow cytometry on day 16 or 17 of
culture.
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Table 2-4.

Effects of Early-Acting Cytokines on Lymphohemopoietic Colony
Fonnation

Number of Colonies/6 dishes
Analyzed by Flow Cytometry
Growth Factors

Lymphomyeloid

Lymphoid

Myeloid

Small
GMIM

Total

Experiment 1
SF,
SF,
SF,
SF,

IL-7,
IL-7,
IL-7,
IL-7,

Ep
Ep, IL-ll
Ep, G-CSF
Ep, IL-12

1
17
6

8

4
4
9
7

12
40
42
41

20
81
92
62

37
142
149
118

61

76

104
99

187
178

19
9

35
69

71
78

Experiment 2
SF, IL-7, Ep, IL-l1
SF, IL-7, Ep, IL-ll, IL-3

13
3

9
0

Experiment 3

SF, IL-7, Ep, IL-l1
13
SF, IL-7, Ep, IL-11, IL-la 0

4

o

Lin- Sca-l + cells were cultured at a concentration of 50 cells per dish. Six dishes were
examined on day 16 or 17 of culture.
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Table 2-5.

Comparison of the Incidences of Lymphohemopoietic Progenitors Present
in Two Femora and Two Tibiae of a Normal Mouse and a Mouse Treated
with 5-FU

Normal mouse

5-FU-treated mouse

single-step
assay

two-step
assay

two-step
assay

Nucleated bone marrow cells

(4.6 + 0.5) x 107

(4.3 + 0.6) x 107

(1.4 + 0.6) x 107

Lin- Sca-l + cells

(1.4 + 0.4) x 105

(8.7 + 2.9) x 104

(2.9 + 2.0) x 104

Colony forming efficiency

40 + 180/0

31 +7 %

41 +6%

Percent of lymphomyeloid
colonies

12+ 5%

18 + 10%

38+6%

Estimated number of
lymphohemopoietic
progenitors

3,400 + 600

4,700 + 2,200

1,100 + 600

Lin" Sca~ 1+ progenitors were cultured in the presence of IL-ll , SF, IL-7 and Ep. Primary
colonies from 5-FU-treated and normal mice were replated on day 11 and day 8 of primary
culture respectively. Means and standard deviations of four experiments for each group.
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Table 2-6.

Colony #
1
2
3

4
5
6

7
8
9
10
11
12
13

The Myeloid Lineage Potential of the Progenitors

Myeloid lineage expression
nmEMastMe

runE
nm
nrn
m
nmMast
nmEMast

B220+ cells

+
+
+
+

nm
nm
nm
run
run
None

+

Initial methylcellulose cultures were established with SF, IL-7, Ep and IL-ll. One half of
each colony was lifted from semisolid culture on day 11 and was placed in liquid culture
containing IL-3, PWM-SCM and Ep. Myeloid lineage expression was examined on day 4
of secondary culture, and the remaining portion of each colony was harvested and analyzed
by flow cytometry on day 19 of culture. Abbreviations: n, neutrophil; ffi, macrophage; E,
erythrocyte; Mast, mast cell; M, megakaryocyte; e, eosinophil.

Figure 2-1. (A) A representative B-Mix colony containing B-Iymphoid and
myeloid components. This colony was derived from Lin- Sca-l + cells of normal
mice grown in the presence of SF, IL-7, Ep and IL-ll for 16 days. (B)
Magnification of a portion of the same colony revealing (1) typical B-Iymphoid
clusters and (2) erythroid components.

Figure 2-2. Detection of B220+ pre-B cells by flow cytometric analysis. (A)
Establishment of the specificity of the flow cytornetric analysis to detect pre-B cells
present at varying percentages in standardized samples. The discrepancy between
the number of events acquired and the number of events reported in the 100% pre-B
cell sample was caused by exclusion of debris by forward scatter gating and dead
cells by PI staining. (B) Fluorescence histograms of (C) isotype control and (E)
"analysis of the B-Mix colony shown in Fig. 1.
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INTRODUCTION

IL-3 is a glycoprotein with an approximate weight between 22 and 32 kDa
depending on the degree of N-linked glycosylation. Its three dimentional structure is
believed to have 5 alpha helical domains with one disulfide bond stabilizing the structure.
The IL-3 receptor is a heterodimeric receptor composed of a unique alpha subunit and a
beta subunit that is common to the GM-CSF and IL-5 receptors. Signal transduction
requires the binding of IL-3 by the alpha subunit and the subsequent formation of a
disulfide bond between the alpha and beta subunits (1,4). In addition to the common beta
subunit, murine cells have an IL-3 specific beta subunit which is functional but to a lesser
degree than the common beta subunit (5). Formation of a functional signal transducing IL3 receptor complex results in the rapid phosphorylation of tyrosine, serine and threonine
residues (6-12); however, the receptor has no intrinsic kinase activity (7). In defining the
segments of the beta subunit that are essential for signal transduction and activation of
second messenger cascades, investigators have made use of specific deletion mutants.
Kinoshita et a1. examined the supression of apoptotic death of IL-3 dependent murine proB and myeloid progenitor cell lines. Their studies revealed that proliferation and prevention
of apoptosis are mediated by different second messenger cascades which are activated by
distinct segments of the beta subunit. Truncation of the C-terminal cytoplasmic domain of
the beta subunit revealed that the membrane proximal region was responsible for the
activation of c-myc and the prevention of apoptosis, while the distal region was responsible
for the activation of p21ras cascade and the stimulation of proliferation (13). P21ras
activates phosphitidyl choline specific phospholipase C, which in-tum increases the
concentration of diacylglycerol, activating protein kinase C (PKC). PKC phosphorylates

raf-l which causes the phosphorylation of MAP kinase and the induction of the
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transcription factors

c~foslc-jun

(14-16). Sato et al. created truncation mutants of the

human common beta subunit. Deletion of amino acids 626 - 881 resulted in no activation
of the p21ras cascade and no induction of the c-foslc-jun transcription factors or p70 S6
kinase, a tyrosine kinase responsible for the induction of the ribosomal protein S6.
Deletion of amino acids 455 - 517 resulted in no activation c-myc or pim-l a cooperative
second messenger expressed only in hematopoietic cells (6,17). The membrane proximal
region is also associated with activation of the Janus kinase (Jak)-2, and signal transducer
and activator of transcription (ST AT)-5, pathway in addition to induction of c-myc and
pim-l (18-20). On phosphorylation, the STAT proteins dimerize and bind to specific
response elements in the promoter regions of target genes and modulate their transcription.
Two classes of STAT binding sites, the interferon stimulated response element and the
interferon gamma activation site (GAS), have to date been identified (19). Recently,
Nagata et al. discovered that IL-3 activates not only STAT5, but also Tyk2, STATI and
STAT3 in several IL-3 dependent murine cell lines (20).
In our laboratory, Hirayama et al. recently developed a two-step clonal culture
assay capable of supporting the differentiation of lymphohemopoietic progenitors along
both the B-cell and the myeloid lineages under stromal cell-free conditions, and this assay
was used to identify IL-3 as a negative modulator of B-Iymphopoiesis (21, 22).
Subsequently, a single-step assay was developed to identify and characterize the noosynchronized population of lymphohemopoietic progenitors present in normal mice (23).
In this assay, enriched marrow cells from normal mice were plated in semisolid culture
containing combinations of cytokines similar to those in the primary culture of the two-step
assay. After 16 to 17 days of culture, the dishes were examined with an inverted
microscope, and all colonies except small granulocyte-macrophage (GM) and macrophage
(M) colonies were harvested for flow cytometric analysis of B220+ pre-B cells. I identified
a population of lymphohemopoietic progenitors capable of generating lymphomyeloid
colonies, colonies containing both B-Iymphoid and myeloid lineage cells, in SF, IL-7 and
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Ep alone. However, the majority of lymphohemopoietic progenitors present in nonnal
mice require IL-ll in addition to SF, IL-7 and Ep to support colony formation.
Approximately 5% of the colony-forming Lin- Sca-l + progenitors from nonnal mice gave
rise to lymphoid restricted pre-B cell colonies. These progenitors were capable of colony
formation in the presence of SF, IL-7 and Ep, and the addition of a synergistic triggering
factor did not significantly increase colony formation by these progenitors. Finally, I
detennined that treatment with 5-FU decreased the number of lymphohemopoietic
progenitors to approximately one-fourth the number present in a normal mouse while
eliminating the population of progenitors that give rise to the B-Iymphoid restricted
colonies. Since the single-step assay is capable of identifying actively proliferating LinSca-l + lymphohemopoietic and committed B-lymphoid progenitors, it provided an
excellent method for the study of the earliest processes of B-Iymphopoiesis. I have utilized
the single-step assay to examine the proliferation of lymphohemopoietic progenitors and
their commitment to the B-Iymphoid lineage, and to characterize the effects of IL-3 on
proliferating lymphohemopoietic and early committed B-Iymphoid progenitors.
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MATERIALS AND METHODS

Growth factors.
Purified recombinant murine SF (the ligand for c-kit) was provided by Genetics
Institute Inc. (Cambridge, MA). Purified recombinant human IL-7 was provided by Dr. C.
Faltynek (Sterling Drug Inc., Malvern, PA). Medium conditioned by CHO cells genetically
engineered to produce murine IL-3 at a high titer (-70,000 U/ml) was a gift from Dr. T.
Sudo (Biomaterial Research Institute, Yokohama, Japan). Purified recombinant human IL11 was provided by Dr. P. Schendel (Genetics Institute). Purified human Ep was provided
by the Genetics Institute Clinical Manufacturing Group.

Monoclonal antibodies (mAbs).
See Materials and Methods of Chapter 2.

Purification of progenitor cells.
See Materials and Methods of Chapter 2.

Culture of progenitors in liquid or semisolid conditions.
Fifty enriched cells were plated in either 1 ml of liquid in one well of a 24 well flat
bottom tissue culture plate (Becton Dickinson Labware, Lincoln Park, NJ) or 1 ml of
semisolid methylcellulose culture in a 35 nun suspension culture dish (Becton Dickinson
Labware, Lincoln Park, NJ). The materials and methods are discussed in Chapter 2. The
concentrations of cytokines used in culture are as follows: SF, 100 ng/ml; IL-3 CHO-CM,

200 U/m!; IL-7, 5 ng/ml; IL-ll, 100 ng/ml and Ep, 2 U/ml.
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Two-step methylcellulose culture assay for lymphohemopoietic progenitors.
See Materials and Methods of Chapter 2. In experiments requiring cultured pre-B
cells, pre-B cell colonies were harvested and then subjected to flow cytometric cell sorting
for B220+ and PI- cells present in the lymphoid window (24).

The single-step assay for the identification of lymphohemopoietic progenitors present in
nOffilal mice.
See Chapter 2.

Identification of lymphohemopoietic progenitors present in primary suspension cultures.
Enriched progenitors from 5-FU-treated mice were plated in suspension culture
containing IL-II, SF, IL-7 and Ep at a concentration of 50 cells per ml. At various time
points the total nucleated cell count was determined and the cells were washed 3 times with
a-MEMlIO% FCS. A portion of the cells were replated in I ml of semisolid culture
containing IL-Il, SF, IL-7 and Ep at a concentration maximizing the number of colonies
per dish without sacrificing clonality. The secondary colonies present in culture were then
examined with an inverted microscope from 12 to 16 days after replating, depending on the
duration of the primary culture, and all colonies except small GM and M colonies were
harvested for F ACS analysis.

Exposure of proliferating progenitors to IL-3.
Fifty enriched progenitors were plated in 1 ml of suspension culture containing SF,
IL-l1, IL-7 and Ep. On the designated day, IL-3 was added to each culture for the
appropriate exposure period. At the conclusion of the exposure period to IL-3, the IL-3
was removed by washing the cells 3 times with 10 ml of a-MEMlIO% FeS. After
washing, the cells were recultured in lml of suspension culture containing SF, IL-ll, IL-7
and Ep. After 11 days of total primary suspension culture, as in the two-step assay for
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lymphohemopoietic progenitors, the pre-B cell colony forming ability was assessed by
preparing 6 dishes of semisolid media containing SF and IL-7 for each exposure group and
culturing 1/200th of the cells present in each condition per dish. The presence or absence
of pre-B cell colonies was noted 12 days after initiation of the lymphoid cultures.
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RESULTS

Commitment of primitive lymphohemopoietic progenitors to the B-Iymphoid lineage.
Since the single-step assay is capable of supporting and identifying colony
formation by actively proliferating lymphohemopoietic and committed B220 negative Blymphoid progenitors, progenitors that give rise to lymphomyeloid colonies and Blymphoid colonies, I utilized the single-step assay to examine the proliferation of
lymphohemopoietic progenitors and their commitment to the B-Iymphoid lineage. Fifty
enriched progenitors were cultured per well in 1 ml of suspension culture containing IL-ll,
SF, IL-7 and Ep for replating on days 4, 5, 6, 7, 9 and 11 of primary culture. On the
designated day of replating, the total nucleated cell count (TNCC) was determined, and a
portion of the cells present in primary culture were replated into methylcellulose culture
containing a combination of cytokines identical to the primary culture, IL-l1, SF, IL-7 and
Ep. After 12 to 16 days in culture, approximately 21 days after the initiation of the primary
suspension culture, in situ examination of the colonies present in secondary culture was
performed. All colonies except small GM and M colonies less than 2,000 cells were
harvested for FACS analysis. After in situ examination for myeloid lineage expression and
FACS analysis for the presence of B220+ pre-B cells, colonies in secondary culture were
designated Lymphomyeloid, B-Iyrophoid, Myeloid, or GM and M. The results of these
replating experiments are presented in Table 3-1. Of the colonies appearing in secondary
cultures initiated by cells replated on days 4, 5 and 6, only lymphomyeloid, myeloid and
GM and M colonies were identified. Interestingly, on day 7 of culture, of the colonies
expressing the B-Iymphoid lineage, 60% were identified as lymphomyeloid while 40%
were identified as being B-Iymphoid. In the cultures initiated with cells replated on days 9
and 11, only B-Iymphoid and GM and M colonies appeared in secondary culture. These
results suggest that on days 0 through 6 the lymphohemopoietic progenitors proliferate.
On or about day 7, the lymphohemopoeitic progenitors begin to commit to the B-Iymphoid
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lineage, generating B-Iymphoid restricted progenitors and finally by day 9 of culture, the
commitment to the B-Iymphoid lineage appears to be complete and the proliferation of
committed B-Iymphoid progenitors takes place. However, it could be argued that the
appearance of B-Iymphoid restricted progenitors on day 7 of culture could be attributed to a
small population of committed B-Iymphoid progenitors that require 7 days of culture to
expand to detectable levels. To dispel this argument, we attempted to determine that there
were no committed B-Iymphoid progenitors in the initial population and to examine the
kinetics of commitment of individual enriched marrow cells. In a series of 7 experiments
209 enriched progenitors from normal mice were cultured in the presence of IL-ll, SF, IL7 and Ep for a minimum of 16 days. Of these progenitors, all expressed cells of the
myeloid lineage and no committed B-Iymphoid progenitors were identified, data not
shown. The kinetics of commitment of indivdiual progenitors was examined by plating
enriched progenitors in semisolid culture containing IL-ll, SF, IL-7 and Ep for 3, 4, 6 and
11 days, at which time primary colonies were harvested and were replated in semisolid
culture containing identical cytokines as the primary culture. Indivdiual primary colonies
that were replated on days 3 and 4 of primary culture

a~d

expressed the B-Iymphoid lineage

gave rise only to lymphomyeloid colonies in secondary culture. Of the primary colonies
replated on day 6 which expressed B-Iymphoid potential, two-thirds gave rise only to
lymphomyeloid colonies while the remaining third gave rise to both lymphomyeloid and Blymphoid colonies in secondary culture. Finally, of the individual colonies replated on day
11 of primary culture which expressed the B-Iymphoid lineage, only B-Iymphoid colonies
were identified in secondary cultures, data not shown. These observations indicate that
enriched progenitors from mice treated with 5-FU, when cultured in permissive culture
conditions first proliferate for approximately 6 days prior to commitment to the B-lymphoid
lineage on or about day 7.
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Timed exposure to IL-3.
Knowing that IL-3 exerts a negative modulatory effect on early B-Iymphopoiesis by
progenitors isolated from both 5-FU treated (21,22) and normal mice (23), and having
demonstrated that early B-Iymphopoiesis by progenitors from 5-FU treated mice apparently
proceeds through somewhat discrete stages, I attempted to discern upon which stage of
early B-Iymphopoiesis IL-3 exerts its negative modulatory effect. In order to do this, IL-3
was added for 48 or 72 hour intervals to permissive suspension culture conditions
containing IL-II, SF, IL-7 and Ep. Fifty enriched progenitors were cultured in suspension
culture containing SF, IL-ii, IL-7 and Ep for a total of 11 days and were then recultured
into lymphoid specific semisolid culture containing SF and IL-7 to assess the B-lymphoid
potential. IL-3 was added on the designated day and removed by washing as shown in
Figure 3-1. Enriched progenitors cultured in the absence of IL-3 for 11 days gave rise to
72+7 pre-B cell colonies per dish in secondary culture. Interestingly, exposure of
proliferating lymphohemopoeitic progenitors to IL-3 on days 4 to 6 of culture increased the
number of pre-B cell colonies appearing in culture to 125+ 14 per dish (p>O.OO 1) in
secondary culture. This observation was similar to our previously published observation in
which 48 hour exposure to IL-3 from day 0 to day 2 increased the number of pre-B cell
colonies appearing in secondary culture approximately 100% above that of control (22). In
an additional experiment, proliferating progenitors exposed to IL-3 for 48 hours gave rise
to 49+8 pre-B cell colonies per dish, 50% higher than the control group. Despite the
positive effect of IL-3 on proliferating lymphohemopoietic progenitors, exposure of
committed B-Iymphoid progenitors to IL-3 beyond day 6 of culture, abrogated B-cell
potential in secondary culture. These results indicate that 48 hour interval exposure of
proliferating lymphohemopoietic progenitors to IL-3 accentuates the formation of
lymphohemopoietic progenitors, while 48 hour exposure of early committed B-Iymphoid
progenitors to IL-3 abrogates B-cell potential.
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Proliferation of lymphohemopoeitic progenitors in the presence of IL-3.
Having demonstrated that lymphohemopoietic progenitors exist in primary culture
for approximately 6 days, and having shown that interval exposure from day 4 to day 6
accentuates the expression of the B-Iymphoid lineage in secondary culture, I was quite
puzzled by the previously reported observation, that continuous exposure of proliferating
progenitors to IL-3 for 4 or more days inhibited the expression of the B-Iymphoid lineage
in secondary culture. Therefore, I examined the kinetics of the proliferation of
lymphohemopoietic progenitors in the absence and in the continuous presence of IL-3. In
this experiment, 50 enriched progenitors from mice treated with 5-FU were cultured in
suspension culture containing IL-l1, SF, IL-7, Ep and IL-3 for 84,90,96, 102, and 108
hours. At each time point the TNCC was detennined, the cells were thoroughly washed
and a portion of the washed cells were replated in the conditions of the single step-assay.
Secondary cultures were examined after 16 days for the presence of lymphomyeloid and Blymphoid colonies. In control cultures, 50 cells were cultured in the presence of IL-iI,
SF, IL-7 and Ep, and at 96, 120, 144, 168 and 216 hours the TNCC was determined and a
portion of the cells were replated in the conditions of the single-step assay. The total
number of lymphohemopoietic progenitors present in culture was calculated and the
proliferation of lymphohemopoietic progenitors in the presence and in the absence of IL-3
is diagrammed in Figure 3-2. The maximum proliferation of lymphohemopoietic
progenitors in the absence of IL-3 occurred at 144 hours, and by 216 hours no
lymphohemopoietic progenitors were identified. However, in the presence of TI...-3 the
degree and the duration of proliferation of the lymphohemopoietic progenitors was altered.
In the presence of IL-3 the maximum proliferation of lymphohemopoietic progenitors
occurred at 96 hours, 48 hours earlier than in the absence of IL-3, and the maximum
amount of proliferation of lymphohemopoietic progenitors in the presence of TI...-3 was
approximately 10 fold lower than in the absence of IL-3. Interestingly at 96 hours, more
lymphohemopoietic progenitors were identified in the cultures containing IL-3 than were
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identified in the cultures in which IL-3 was absent, supporting the conclusion that IL-3
accentuates the proliferation of lymphohemopoietic progenitors. Additionally, no restricted
B-Iymphoid coloni~s were identified in the cultures containing IL-3 as expected. Thus,
short interval exposure of proliferating lymphohemopoietic progenitors to IL-3 appears to
accentuate their proliferation while long interval exposure to IL-3 appears to shorten the
duration of the proliferation of lymphohemopoietic progenitors.

Pre-B cell formation in the presence of IL-3.
Since very early committed B-Iymphoid progenitors, those present in culture from
day 6 to day II, are very sensitive to the inhibitory effects of IL-3, I attempted to determine
the point at which the committed B-Iymphoid progenitors became non-sensitive to the toxic
effects of IL-3. I cultured enriched progenitors from mice treated with 5-FU in semisolid
culture containing IL-ll , SF, IL-7 and Ep for 14 days, at which time twenty primary
colonies were harvested, pooled and sorted by flow cytometry for Mac-l ~, Gr-l-, TER 119and PI- cells. The sorted cells were then cultured at a concentration of 5xl04 cells/ml in a
secondary suspension culture containing SF, IL-I1, IL-7 and Ep in the presence and
absence of IL-3 for 10 days. The cultures were expanded as necessary and were analyzed
by flow cytometry for the presence of B220+ pre-B cells. The dot plot analyses presented
in Figures 3-3 A and B are representative of cells after culture in the absence and the
presence of IL-3 respectively. Only PI- cells present in the lymphoid window (25) were
included in these analyses. As can be seen, a distinct population ofB220+ pre-B cells
developed in both the absence and presence of IL-3. Calculation of the total number of preB cells present in the cultures with and without IL-3 was (2.3 + 0.5) x 105 and (3.5 + 3.3)
x 105 respectively. Therefore, by day 14 of culture the committed B-cell progenitors are no
longer sensitive to the cytotoxic effects of IL-3, and IL-3 has little or no negative effect
upon their proliferation.
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Pre-B cell proliferation in the presence of IL-3.
A pure population of cultured pre-B cells was obtained by sorting pooled pre-B cell
colonies for B220+ apd PI- cells by flow cytometry. These sorted cells were then cultured
in triplicate suspension cultures at a concentration of 5xl()4 cells per ml. The cell number
was then determined 3, 4 and 6 days after initiation of the culture, and all cultures were
expanded on day 4 of culture. As can be seen in Figure 3-4, IL-3 had no effect, positive or
negative, on the proliferation of cultured pre-B cells.
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DISCUSSION

It appears that the primitive lymphohemopoietic progenitors from mice treated with
5-FU proliferate for 6 to 7 days prior to their commitment to the B-Iymphoid lineage. Blymphoid committed progenitors can first be identified on day 6 or 7 of primary culture in
conjunction with lymphohemopoietic progenitors, and beyond day 9 of culture, no
lymphohemopoietic progenitors, only committed B-Iymphoid progenitors can be identified.
Although it is possible that the pooled progenitors used in a majority of these studies are
contaminated by committed B-Iymphoid progenitors, the observed proliferation and
disappearance of the lymphohemopoietic progenitors cannot be disputed, and it is probable
that the lymphohemopoietic progenitors generate the majority of the committed B-Iymphoid
progenitors observed. Therefore, early B-Iymphopoiesis by this population of
lymphohemopoietic progenitors appears to proceed through 3 stages: a lymphohemopoietic
proliferative stage; a commitment stage and an early committed B-Iymphoid proliferative
stage that ends in the production of B220+ pre-B cells.
It has been previously reported that IL-3 appears to have a negative modulatory role
on the process of early B-Iymphopoiesis by progenitors isolated from 5-FU treated and
normal mice (21-23). Having identified three stages of early B-Iympbopoiesis by
lymphohemopoietic progenitors the stage in which IL-3 exerts its negative modulatory
effect was determined. Similar to the previously published results, 48 hour exposure of
proliferating lymphohemopoietic progenitors, between day 4 and 6 of culture, increased the
number of pre-B cell colonies appearing in secondary culture approximately 50 to 70%.
However, when proliferating committed B-Iymphoid progenitors, present in culture from
day 7 to day 11, were exposed to IL-3 the B-Iymphoid potential was abrogated, and on day
14 and beyond IL-3 exerted no negative effect on committed B-Iymphoid progenitors.
These observations suggest the early committed B-Iymphoid proliferative stage, the stage
marked by the proliferation of committed B-Iymphoid progenitors ending in the fonnation
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of B220+ pre-B cells, could be further subdivided based on the inhibition or lack thereof by

IL-3.
Hardy et al. 4as established a series of stages of B-Iymphoid differentiation by
progenitors expressing B220 (25). These stages have been designated A, B, C, C' and D.
Briefly, the most primitive identifiable committed B-Iymphoid progenitors express B220
and CD43 and are characteristic of the progenitors present in stage A, while stage D is
composed of B220+, CD43-, HSA+, BP-l + and cytoplasmic Jl chain positive pre-B cells
(25-27). Previously, several investigators have established IL-3 dependent B-Iymphoid
progenitor, pro- and pre-B cell lines, thus implicating IL-3 as a very important regulator of
B-Iymphopoiesis (28-32). However, in each case these cell lines were at least positive for
the expression ofB220 and several of them were pre-B cell lines. We have demonstrated
that IL-3 has no negative effect upon the proliferation of the committed B-Iymphoid
progenitors present on or after day 14 of culture, and it is quite possible that the IL-3
dependent cell lines reside in a similar stage of differentiation as the progenitors present in
culture on day 14 and later.
Interestingly, when lymphohemopoietic progenitors were cultured in the presence
of IL-3, their progeny could be identified in culture for a maximum of 102 hours. The
proliferation of lymphohemopoietic progenitors reached a maximum at 96 hours,
approximately 48 hours prior to the maximum in the absence of IL-3. Additionally, the
maximum number of lymphohemopoietic progenitors present at 96 hours, although at that
time point was greater than the control, was approximately 10 fold less than the maximum
number of lymphohemopoietic progenitors generated in the absence of II...- 3. The
observation that short exposure of proliferating lymphohemopoietic progenitors to IL-3
enhances the proliferation of lymphohemopoietic progenitors and that constant exposure
decreases both the duration and the degree of proliferation of lymphohemopoietic
progenitors indicates that IL-3 has a very complex mechanism of action. If 1L-3 functions
by stimulating proliferation and differentiation while sacrificing the self-renewal, then short
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exposure of proliferating progenitors to IL-3 may increase proliferation without
significantly altering self-renewal while, exposure for longer periods may have a negative
effect on self-renewal in an attempt to generate larger numbers of more mature hemopoietic
cells. This would account for the observation that short exposure increases the production
of lymphohemopoietic progenitors while longer exposure increases the rate of
differentiation. Similar results have been obtained in my examination of the effect of IL-3
on the maintenance of long term reconstitution potential of primitive hemopoietic
progenitors in that self-renewal potential is more rapidly lost by progenitors cultured in the
presence of IL-3 when compared with progenitors cultured in the absence of IL-3 (33).
Unfortunately, because of the inability to significantly purify the early committed Blymphoid progenitors, I am unable to determine whether IL-3 directly inhibits committed
B-Iymphoid progenitors. Since IL-3 is a very strong stimulus for the proliferation of
myeloid lineage cells, it is possible that the observed cytotoxic effect is an indirect effect
mediated by other cells present in the cultures. Regardless of the exact mechanism, be it
direct or indirect, IL-3 appears to function as a negative modulator of the proliferation of
the earliest committed B220- and B220+ B-Iymphoid progenitors. In culture, my results
corroborate the previous in vivo findings of Cockayne et aI., implicating IL-3 as a negative
modulator of B-Iymphopoiesis (34). In their studies, they developed transgenic mice
expressing antisense IL-3 RNA, essentially blocking IL-3 production in these mice. Their
mice developed either a lymphoproliferative syndrome or neurologic dysfunction. Of
interest to me is the lymphoproliferative syndrome which is marked by an aggressive
proliferation of B220+/sIgM- B-lineage blasts throughout the mice. Together these results
suggest that IL-3 is a very important negative effector of B-Iymphopoiesis, dampening the
proliferation of the earliest B-Iymphoid committed progenitors.
Finally the apparent capacity of IL-3 to shorten the duration and the degree of selfrenewal of lymphohemopoietic progenitors suggests that great caution should be exercised
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in using IL-3 to expand lymphohemopoietic progenitors in vitro as it may induce their
differentiation.
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Table 3-1. Kinetics of Lymphohemopoietic Progenitor Proliferation and Commitment

No. of cells
Day of
. replatedldish
suspensionin secondary_ _ _ _---=-A..:::n=a=.ly/-=z=e.=,d_ _ _ _ __
culture
Lymphomyeloid B-Iymphoid Myeloid GM&M Total
culture TNCC

4
5
6
7

9
11

5xl03
lxl04
1.4xl04
1.7xl05
1.1xl06
2.8xl06

50
50
100
200
500
1/200th

2+1
1+1
2+2
6+2
0
0

0
0
0
4+2
2+1
74+7

3+3 24+5 27+5
1+1 18+4 19+3
2+1 21+2 24+3
0+1 103+17 113+17
0+0 15+4 18+4
0
ND
ND

Fifty post 5-FU Lin- Sca-l + progenitors were cultured in suspension culture in the presence
of SF, IL-ll, IL-7 and Ep. On the designated day of suspension culture the total nucleated
cell count (TNCC) was determined and a sample of the cultured cells was plated in
semisolid culture containing SF, IL-l1, IL-7 and Ep. After 16 to 17 days of secondary
culture the dishes were examined. All colonies except small OM and M colonies were
harvested for flow cytometric analysis. Data represent mean and standard deviation of 10
culture dishes.

Figure 3-1. Interval exposure of proliferating progenitors to IL-3. Fifty enriched
progenitors were cultured in primary suspension culture containing IL-ll , SF, IL-7
and Ep. IL-3 was added to the cultures for the designated exposure period and was
removed by washing. After washing, the cells were resuspended in the original
culture conditions. On day 11 1/200th of the cells present were replated in
semisolid lymphoid suspension culture containing SF and IL-7 to assess the Blymphoid potential. Pre-B cell colonies number represents the mean and standard
deviation of 6 dishes, p <0.001.

IL-3
Exposure

Day of primary culture

colonie s no.
4

None

Pre-B cell

5

6

7

8

9

10

11
72+7

Day 4-6

125+14

Day 4-7

1+1

Day 5-7

O±O

Day 7-9

O±O

Day 9-11

1+1

Figure 3-2. Proliferation of lymphohemopoietic progenitors in the presence of
IL-3. Fifty enriched progenitors were cultured in suspension culture containing IL11, SF, IL-7 and Ep in the presence or absence of IL-3. The lymphohemopoietic
progenitors present in cultures containing IL-3 were examined at 84, 90, 96, 102
and 108 hours, while progenitors cultured in the absence of IL-3 were examined at
96, 120, 144, 168 and 216 hours. The number of progenitors identified at 108
hours in the presence of IL-3 and at 216 hours in the absence of IL-3 was O.
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Figure 3-3. Generation of B220+ pre-B cells in the presence and absence of IL3. Two color analysis of day 14 Mac-l-, Gr-l-, TERl19- and PI- colony cells after
9 days of suspension culture in SF, IL-l1, IL-7 and Ep (A) and SF, IL-l1, IL-7,
Ep and IL-3 (B). The analysis includes only PI- cells present in the lymphoid
window.
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Figure 3-4. Proliferation of pre-B cells in the presence and absence of IL-3.
B220+ pre-B cells were sorted from pooled cultured pre-B cell colonies and were
cultured in suspension culture. The data represent mean and standard deviation of
triplicate cultures.
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Chapter IV
Late Divergence of B-Lymphoid and Myeloid Lineages:
Evidence Supporting a Model of Random Restriction of Lineage Potential,
and the Possible Existence of a Bipotential B-Lymphoid/Macrophage Progenitor
Timothy C. Ball
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INTRODUCTION

The most widely accepted view of the differentiation of primitive cell-cycle donnant
lymphohemopoietic progenitors holds that only the most primitive progenitors have
lymphohemopoietic potential. As these progenitors begin to proliferate, it is believed that
the divergence of the B-Iymphoid and the myeloid lineage potentials is occurs, forming
lymphoid and myeloid restricted progenitors. These lymphoid and myeloid restricted
progenitors give rise to cells of the lymphoid and myeloid lineages, as is shown in Figure
1-1. Only recently with the development of the two-step and the single-step assays for
lymphohemopoietic progenitors, has it been possible to examine the B-Iymphoid and the
myeloid potential of primitive hemopoietic progenitors (1, 2). Prior to this, examination of
the lineage potential of individual primitive hemopoietic progenitors was restricted primarily
to the myeloid lineage. Till et al. developed the first quantitative assay for primitive
hemopoietic progenitors while investigating the reconstitution of lethally irradiated mice
with donor marrow. Macroscopic nodules of proliferating hemopoietic cells were noted to
be present in the spleens of the irradiated recipient mice 7 to 14 days after transplantation.
These nodules were called spleen colonies, and the progenitors giving rise to these colonies
were designated colony forming unit-spleen (CFU-S) (3). These progenitors were found
to have high proliferative capacity and differentiative capacity along with self-renewal
capacity, thus fulfilling the three criteria of stem cell as defined by Till (4). In 1979
Hodgson et aI. identified two populations of CFU-S which formed spleen colonies that
were macroscopically identifiable 10 or 13 days after transplantation (5). They also found
that mice treated with the chemotherapeutic drug 5-FU (6) retained only the population of
CFU-S which formed spleen colonies on day 13. In 1982 Magli et al. examined the
appearance and disappearance of spleen colonies over time, and their results corroborated
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the observations of Hodgson et al. suggesting two distinct populations of CFU-S; a more
mature population giving rise to spleen colonies present on day 8 and a more primitive
population giving rise to spleen colonies present on day 12 after transplantation (7).
Throughout these investigations, only myeloid lineage cells, macrophages, granulocytes,
megakaryocytes and erythroid progenitors were found to be present in spleen colonies
(1,2). The lack of lymphoid differentiation in such an important lymphoid organ as the
spleen suggested that these cells were myeloid restricted stem cells with self-renewal
capacity. As late as 1979, definitive demonstration of B-Iymphoid expression by CFU-S
had not been produced (8-10). It was not until 1984 that individual day 12 CFU-S were
demonstrated to have the ability to give rise to cells of both B- and T-Iymphoid lineages
upon reinjection into irradiated mice (11). Lepault recently corroborated these results and
further established that 100% of day 12 CFU-S and many day 8 CFU-S have both B- and
T-Iymphoid potential (12).
Results obtained in the characterization of the lymphohemopoietic progenitors
present in normal mice and in the study of the proliferation and commitment of primitive
lymphohemopoietic progenitors (2, 13) suggest that the divergence of the B-Iymphoid and
myeloid lineages does not occur as hypothesized in the conventional view of hemopoietic
differentiation. Therefore, to further examine the mechanism of lineage divergence, I used
the two-step assay and a modified version of the two-step assay to examine the lineage
expression of Lin- Sca-l + progenitors from 5-FU treated and normal mice. Assuming that
the culture systems are equally permissive for the expression of all myeloid lineages, the
large degree of heterogeneous expression of the myeloid lineage by individual progenitors
is consistent with previous observations and supports a stochastic model of lineage
commitment (14). Of the lymphohemopoietic progenitors from normal mice, the majority
gave rise to only 1 or 2 myeloid lineages in addition to the B-Iymphoid lineage, and it was
these progenitors that were most sensitive to the cytotoxic effects of 5-FU. No significant
positive relationship between the number of myeloid lineages expressed and the
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coexpression of the B-Iymphoid lineage was identified. The conventional view of
hemopoietic differentiation in which the divergence of lymphoid and myeloid lineages
occurs very early would predict such a positive relationship, since only the most primitive
progenitors would retain both lymphoid and myeloid potential. Assuming the culture
system is equally permissive for the differentiation of all myeloid lineages, these results
support a model of random restriction of lineage potential with a late divergence of the Blymphoid and the myeloid lineages, possibly resulting in the formation of a bipotential Blymphoid/macrophage progenitor.
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MATERIALS AND METHODS

Growth factors.
Conditioned medium (CM) of Chinese hamster ovary (CHO) cells that had been
transfected with an expression plasmid containing murine SF cDNA was provided by
(Genetics Institute Inc., Cambridge, MA). Purified recombinant human IL-7 was
provided by Dr. C. Faltynek (Sterling Drug Inc., Malvern, PA). Medium conditioned by
CRO cells genetically engineered to produce murine IL-3 at a high titer (-70,000 U/ml) was
a gift from Dr. T. Sudo (Biomaterial Research Institute, Yokohama, Japan). Purified
recombinant human IL-ll was provided by Dr. P. Schendel (Genetics Institute). Purified
human Ep was provided by the Genetics Institute Clinical Manufacturing Group.
Recombinant murine IL-5 was provided by the Genetics Institute. Pokeweed mitogen
spleen conditioned medium (PWM-SCM) was prepared in our laboratory as described
(15).

Monoclonal antibodies (mAbs).
See Materials and Methods of Chapter 2.

Purification of progenitor cells.
See Materials and Methods of Chapter 2.

Culture of progenitors in semisolid conditions.
Fifty enriched cells were plated in 1 ml of semisolid methylcellulose culture in a 35
mm suspension culture dish (Becton Dickinson Labware, Lincoln Park, NJ). the materials
and methods are described in Chapter 2. The concentrations of cytokines used in culture
are as follows: SF, 100 ng/m!; IL-3 eRO-eM, 200 D/ml; IL-5, 12 U/ml; IL-7, 5 ng/ml;
IL-ll, 100 ng/ml; Ep, 2 D/ml and PWM-SCM, 5%.

94
Two-step methylcellulose culture assay for lymphohemopoietic progenitors.
See Materials and Methods of Chapter 2.

The single-step assay for the identification of lymphohemopoietic progenitors present in
nonnal mice.
See Materials and Methods of Chapter 2.

Identification of lymphohemopoietic progenitors in primary suspension cultures.
See Materials and Methods of Chapter 3.
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RESULTS and DISCUSSION

Analysis of B-Iymphoid and myeloid lineage expression by enriched progenitors from
normal and 5-FU-treated mice.
The myeloid and B-Iymphoid lineage potential of enriched progenitors from 5-FUtreated and normal mice were examined in the two-step and a slightly modified version of
the two-step assay in 4 separate experiments, respectively. Briefly, in the two-step assay
for lymphohemopoietic progenitors from normal mice, the primary colonies were harvested
on day 8, and the cells were plated in myeloid suspension culture containing SF, IL-3, IL-5
and Ep and B-Iymphoid suspension culture containing SF and IL-7. The myeloid cultures
were examined 4, 6 and 8 days after initiation of culture, and the B-Iymphoid cultures were
analyzed by FACS analysis for the presence ofB220+ pre-B cells after 11 days of
secondary culture. Enriched progenitors from 5-FU-treated mice were cultured in IL-l1,
SF, IL-7 and Ep for 11 days, at which time the primary colonies were harvested and were
replated into myeloid suspension culture containing PWM-SCM, IL-3 and Ep and
semisolid lymphoid culture containing SF and IL-7. The morphology of the cells present
in the suspension culture was examined 2,4 and 6 days after initiation of the secondary
culture, and the lymphoid cultures were examined after approximately 12 days for the
presence of pre-B cell colonies.
The cumulative results of the experiments in which progenitors from normal mice
were examined are shown in Table 4-1. Individual colonies are grouped together based on
their myeloid lineage expression, and they are then subdivided based upon the absence or
presence of the expression of the B-Iymphoid lineage. From this, the percentage of each
colony type with B-Iymphoid lineage expression was calculated. In agreement with the
previous identification of the percentage of LHP and B-Iymphoid progenitors, 18% of the
Lin- Sca-l + progenitors gave rise to cells of both the B-Iymphoid and the myeloid lineages,
and approximately 5% appeared to be restricted to the B-Iymphoid lineage (2). The most

96

common combination of myeloid lineages expressed by individual progenitors was that of
the neutrophil (n) and macrophage (m) lineages. Nineteen percent of the colonies
expressing nand m were also positive for the expression of the B-Iymphoid lineage. The
second most common pattern of myeloid lineage expression was m, and similarly, 17% of
the macrophage colonies coexpressed the B-Iymphoid lineage. Although the progenitors
expressing these two combinations, nrn and ffi, account for well over half of the colony
forming progenitors, of the remaining progenitors, 55 gave rise to 3 or more myeloid
lineages and of these, 22% percent were identified as lyrnphoh7mopoietic. Calculation of
the mean and standard deviation of these percentages from the 4 separate experiments
indicated that there was no significant difference in the percentage of lymphohemopoietic
progenitors expressing nm,

ffi,

or 3 or more myeloid lineages, although the numbers are

low.
The B-Iymphoid and the myeloid lineage expression of individual progenitors from
mice treated with 5-FU is shown in Table 4-2. The colonies are once again grouped
according to their myeloid lineage expression and are subdivided based on the presence or
absence of the B-Iymphoid lineage expression. Finally, the percentage of each type of
colony expressing the B-Iyrnphoid lineage was calculated. Of a total of 61 individual
progenitors examined, 43% or 26 were identified as being lymphohemopoietic. The most
common myeloid lineage combination expressed by these progenitors was that of the ll, m,
erythroid (E), mast cell (Mast) and megakaryocyte (M), and 31 % of the progenitors giving
rise to this combination also expressed the B-Iymphoid lineage. Interestingly, the next
most common combination of myeloid lineages expressed was nand m, and 640/0 of these
colonies also contained B-Iymphoid lineage cells. Only 2 progenitors gave rise to the
macrophage lineage alone and neither of these expressed the B-Iymphoid lineage.
In Table 4-3 the lymphohemopoietic progenitors identified in Tables 4-1 and 4-2 are
grouped based on the number of myeloid lineages they expressed. As can readily be seen,
treatment with 5-FU dramatically decreased the percentage of lymphohemopoietic
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progenitors expressing only 1 or 2 myeloid lineages. These results support previous
observations which suggest that the progenitors giving rise to larger numbers of myeloid
lineages are more resistant to the cytotoxic effects of 5-FU, whereas the progenitors that
give rise to fewer myeloid lineages are very sensitive to the cytotoxic effects of 5-FU.
Knowing that 5-FU inhibits thymidylate synthase creating a thymidylate deficiency that
kills more rapidly proliferating cells, these results indicate that the progenitors with greater
lineage potentials are proliferating more slowly than are the progenitors with fewer lineage
potentials.
If a hierarchy of differentiation exists, then primitive hemopoietic progenitors
should have the potential to give rise to many myeloid lineages, and as differentiation
proceeds, the resulting more mature progeny should have somewhat restricted lineage
potentials. If the conventional view of hemopoietic differentiation holds, and only the most
primitive progenitors have lymphohemopoietic potential, then alllymphohemopoietic
progenitors must be more primitive than myeloid restricted progenitors. Following this,
one would expect a direct relationship between the number of myeloid lineages expressed
and the expression of the B-Iymphoid lineage to exist. However, examination of the
myeloid lineage expression by lymphohemopoietic progenitors present in normal mice
indicates that no such relationship exists, and further, treatment with 5-FU removes a great
majority of the lymphohemopoietic progenitors with restricted myeloid lineage expression.
These results cast doubt on the conventional model of hemopoiesis which proposes a very
early divergence of the myeloid and the lymphoid lineages in hemopoiesis.
Previously published observations of the lineage expression of individual blast
cells, primitive hemopoietic progenitors, and their daughter cells indicated that the
combinations of myeloid lineages expressed by these progenitors were very heterogeneous
(16-20), and a total of fifteen different combinations of myeloid lineages expressed by
individual progenitors were identified. A stochastic model of progressive random
restriction of lineage potential by differentiating progenitors was developed (14). The Lin-
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Sca-l + progenitors from normal and 5-FU-treated mice were found to give rise to 13 of the
15 combinations previously reported.
The results obtained in this study support a model of hemopoietic differentiation
which includes primitive hemopoietic progenitors resistant to the cytotoxic effects of 5-FU,
that give rise to actively proliferating lymphohemopoietic progenitors with somewhat
restricted myeloid lineage potential that are sensitive to the cytotoxic effects of 5-FU. A
modified version of the stochastic model of progressive random restriction of lineage
potential (14), in which the entire bone marrow compartment isolated on bone marrow
aspiration is represented is presented in Figure 4-1. The shaded cells to the right of the
divider represent the largest population of cells present in bone marrow preparations which
are removed by density gradient centrifugation, negative selection for lineage committed
antigens and Sca-l sorting. The cells to the left of the divider represent the population of
Lin- Sca-l + cells present in nonnal mice. The lightly shaded cells in the population of LinSca-l + progenitors represent those cells sensitive to the cytotoxic effects of 5-FU, and the
cells with no shading are the cells resistant to 5-FU. As can be seen, both normal and 5FU treated populations, contain n, m and B-Iymphoid progenitors, whereas only very few
if any m and B-Iymphoid progenitors are present in the population from 5-FU treated mice.
The model presented in Figure 4.1 also incorporates a progressive random
restriction of lineage potentials that may result in the formation of a bipotential Blymphoid/macrophage progenitor that is capable of giving rise to B-Iymphoid progenitors
and macrophage progenitors. It is important to note that the T -lymphoid lineage is only
mentioned in the most primitive pluripotent lymphohemopoietic progenitor. This is
because at the present time, conclusions regarding the expression of the T -lymphoid lineage
are impossible due to the lack of an in vitro culture system permissive for the differentiation
T -cell progenitors.
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B -lymphoid/macrophage association.
As can be seen in Tables 4-1 and 4-2, virtually all of the lymphohemopoietic
progenitors identified from nonna! and 5-FU-treated mice gave rise to the macrophage
lineage. In Table 4-3, the progenitors identified as expressing both the myeloid and Blymphoid lineages in Tables 4-1 and 4-2 were grouped according to their patterns of
myeloid lineage expression. Surprisingly, 22% of the lymphohemopoietic progenitors
isolated from normal marrow appear to be bipotential B-Iymphoidlmacrophage progenitors.
Over the past 15 years, many observations have been published suggesting an
association between the B-Iymphoid and the macrophage lineages. These observations are
somewhat contradictory to the conventional view of hemopoietic differentiation. Some of
the first evidence suggesting an association between the B-lymphoid and the macrophage
lineage was from observations of leukemic patients, and in cell lines isolated from leukemic
patients. Minowada et al. (21) in 1979 isolated a cell line of human origin that had pre-B
cell characteristics, but was also positive for the Philadelphia chromosome, a marker for
chronic myelogenous leukemia (CML). Since then, a number of investigators have
reported cell lines isolated from CML patients exhibiting both B-Iymphoid and monocytic
characteristics. Several cases of patients with CML who presented with B-Iymphoid blast
crises have also been reported (22-24). Additional reports of acute leukemia with mixed
myeloid and lymphoid phenotypes have also been published (25-28). In 1982 Boyd et al.
demonstrated that treatment of the murine pre-B cell line ABLS 8.1 with the DNA
demethylating drug, 5-azacytidine, gave rise to clones of macrophage-like cell lines (29).
They theorized that alteration of the methylation pattern of the DNA allowed the
transcription of a different series of genes, thus prompting the lineage change from pre-B to
macrophage. They further speculated that there may be a common progenitor of both the
B-Iymphoid and the macrophage lineages. In 1986 Holmes et aI. established murine cell
lines from neonatal bone marrow and fetal liver infected with ras containing viruses that
coexpressed antigens usually restricted to the B-Iymphoid and the macrophage lineage,
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B220 and Mac-I, respectively (30). They theorized, that these cell lines were immortalized
bipotential B-lymphoid/macrophage progenitors as predicted in a model by Till (2)
suggesting that primitive progenitors may express surface antigens of all lineages at very
low concentrations and these aid in differentiation (31). Later, this same group examined
the B220+ Mac-l + cell line isolated from neonatal bone marrow and found that when
stimulated with lippopolysaccharide, it was capable of differentiation into pre-B cells or
into functional macrophages (32). In the same year, Klinken et a1. created EJl-myc
transgenic mice. From these mice several pre-B cell lines were isolated. They found that
the incorporation of v-raj into the EJl-myc pre-B cell lines induced some cells to change
lineage production from pre-B cells, to functional macrophages with rearranged
immunoglobulin genes (33). Further, Sherr et aI. has also demonstrated insertion ofjms,
the CSF-l receptor, into pre-B cells in long term murine lymphoid cultures produced
transformed cell lines capable of producing functional macrophages with rearranged Ig
genes when placed in myeloid culture conditions (34). An overriding observation in all of
these examples, is that only the macrophage lineage has been found in association with the
B-lymphoid lineage. In no case does any other myeloid lineage associate with the Blymphoid lineage in the same manner. McCulloch interprets these observations as aberrant
programming or lineage infidelity (35) whereas, Greaves et a1. argue that there is a transient
period of lineage promiscuity and the afore mentioned examples are actually progenitors
immortalized at specific stages in their differentiation (36).
Prior to the publication of the two-step assay, Cumano et a1. published their
findings regarding the isolation of a population of AA4.1 +, B220-, Mac-I· and Ly6A+ cells
from day 12 murine fetal liver which contained bipotential B-Iymphoidlmacrophage
progenitors (37). They found no combination of cytokines was capable of replacing the
absolute requirement of S 17 stromal cells and IL-7 for proliferation of the bipotential Blymphoid/macrophage progenitors. They established the clonal or single cell nature of
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these progenitors by micromanipulation, and they further examined the ability of additional
cytokines in combination with S 17 cells and IL-7 to support additional myeloid lineage
expression by these progenitors. They observed that the only lineage expressed in
conjunction with the B-Iymphoid lineage was the macrophage lineage. In addition, they
determined that these bipotential progenitors had no long term reconstitution potential when
transferred into irradiated mice. Therefore, they concluded that the bipotential progenitors
were not pluripotent stem cells, but rather, were restricted bipotential Blymphoid/macrophage progenitors.
Examination of the B-Iymphoid and the myeloid lineage potential of the Lin- Sca-l +
progenitors of normal mice revealed that only the macrophage lineage is expressed as a
single myeloid lineage in conjunction with the B-Iymphoid lineage Table 4-1. In addition,
examination of the proliferation of lymphohemopoietic progenitors revealed that the last
myeloid lineage whose expression was identifiable by progenitors retaining B-Iymphoid
and myeloid potential prior to the formation of B-lymphoid restricted progenitors was that
of the macrophage lineage, supporting the conclusion that a bipotential Blymphoid/macrophage progenitor is a nonnal part of B-Iymphopoiesis.

Conventional B220+ B cells and Ly-l +, B220+, Mac-I + B cells.
In conducting the flow cytometric analysis of individual colonies in the single-step
assay, a popUlation cells expressing both the B220 and Mac-l surface antigens was
identified. This popUlation was most readily seen in colonies grown in the presence of IL11 , SF, IL-7, Ep and IL-3. Interestingly, two major subsets of B cells have been identified
as components of the B-Iymphoid lineage. The most well understood subset of B cells has
been designated "conventional" B cells. They express the pan B cell antigen B220 but not
the myeloid lineage antigen Mac-l (38). These B cells are derived from bone marrow stem
cells, and they constitute the predominant population of B cells in n01TI1al mice, greater than
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99% of all B cells (39). These B cells typically produce the classic primary and secondary
antibody responses to T cell-dependent antigens (40, 42).
Hayakawa et ale initially identified a population of B cells that expressed the pan-T
surface antigen Ly-l in 1983. These cells make up the second subset ofB cells. (43,44).
Since then, they have been called "Ly-l" B cells, "CD5+" B cells and "B 1" B cells. Ly-l B
cells have several very distinctive criteria distinguishing them from "conventional" B-cells.
They appear very early in development, approximately day 13 of fetal life, (45, 46) and
they maintain extensive self-renewal potential (47). In fact, only fetal and neonatal liver
and bone marrow preparations have the potential to reconstitute Ly-l B cells, while bone
marrow preparations from mice older than 8 weeks of age fail to reconstitute even minimal
numbers of Ly-l B cells in recipient mice (39). Hardy et al. has proposed a model ofBlymphopoiesis describing the early divergence of an Ly-l B cell progenitor which occurs in
fetal and neonatal life. This divergence leaves a "restricted" lymphohemopoietic progenitor
in adult bone marrow that is incapable of the generation of the Ly-l subset of B cells. Ly-l
B cells have a very specific tissue localization. Virtually no Ly-l B cells are identifiable in
peripheral lymph nodes and spleen, while almost half of all loosely attached B cells
recovered from the peritoneal cavity are Ly-l B cells (38). These cells appear to home to
and remain in the peritoneal, pleural and pericardial cavities at relatively high concentrations
(48, 49). Another distinctive characteristic of Ly-l B cells is their secretion of IgM without
T -dependent antigenic stimulation (50, 51). Ly-l cells are very important in the generation
of serum IgM, and a statistically significant correlation exists between the serum IgM level
and the number of Ly-l B cells present in an animal (52). A majority of the antibodies
produced by Ly-l B cells are encoded by germline genes and do not undergo somatic
mutation (46-53). Of the IgM antibodies produced on a continuous basis by Ly-l B cells,
many are directed against self antigens and appear to playa role in several autoinunune
diseases (37,46, 54). It has been suggested that these autoantibodies may function in the
clearance of senescent cells and removal of denatured proteins as many of their antigenic
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determinants are carbohydrates on glycoproteins and glycolipids (45). However,
according to Hardy, the most appealing theory as to the specificity, spontaneous production
and function of the natural autoantibodies produced by Ly-l B cells is that these
specificity's have been selected into the germ line because such specificity's also react with
many antigens present on frequently encountered pathogens. These therefore, may help in
defense against pathogens presented to the neonate after the concentration of passive
maternal immunoglobulin has begun to decrease and before the active T -dependent immune
system is established (45). The final distinctive criterion of Ly-l B cells is their expression
of the pan-B cell antigen B220, the pan-T cell antigen Ly-l, and the myeloid lineage
antigen Mac-I.
In 1987 Palacios et a1. reported the development of a monoclonal antibody, CC 11,
(55, 56) capable of identifying two distinct populations of B-Iymphoid progenitors present
in the marrow of 5-week old mice (57). The two populations were Cell + and cell-.
The CC 11 + cells were capable of proliferating in the presence of IL-3 and they were also
characteristic of the subset of B cells known as the Ly-l B cells with Ly-l and Mac-I
antigen expression. The CC 11- cells were not capable of proliferating in the presence of
IL-I, IL-2, or IL-3, these cells were characteristic of precursors maintained in WhitlockWitte cultures, "conventional" B cells (57). Unfortunately, no studies have been conducted
to detennine if CC 11 + cells are Ly-l B cells.
Knowing a distinct subset of B cells exists that express not only the B220 surface
antigen, but also the monocyte/macrophage specific antigen Mac-l and that this population
of cells may be capable of proliferation in the presence of IL-3, it is possible that the
population of B220+ and Mac-l + cells identified in the single step assay are progenitors of

Ly-l B cells. It is important to note that characterization of a Ly-l B cell is based upon the
expression of the Ly-l antigen and not the Mac-l antigen. Therefore, further investigation
is necessary to determine if this population of B220+ Mac-I + cells is related to Ly-l B cells.
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The conclusion that an association between the B-Iymphoid and the macrophage
lineages is based on the assumption that the two-step and the single-step assays are equally
permissive for the differentiation and expression of all lineage potentials of an individual
progenitor. In Table 4-4, the incidence of lineage expression by the entire population of
enriched Lin- Sca-l + progenitors from normal and from 5-FU-treated mice presented in
Tables 4-1 and 4-2 is examined. As can be seen, the macrophage lineage is expressed by
greater than 99% of the Lin- Sca-l + progenitors from both normal and from 5-FU treated
mice, and similarly, the neutrophil lineage is expressed by 73% and 97% of the same
progenitors respectively. Interestingly, the E, B, M and the eosinophil (eo) lineages all
have a similar incidence of expression within the populations. The myeloid suspension
culture in which the progenitors from 5-FU were assayed, lacked IL-5, a late acting
proliferative factor which enhances proliferation of the eosinophils, and this difference
probably accounts for the unusually low incidence of identification of the eo lineage in the
progenitors from 5-FU treated mice. Finally, the incidence of expression of the Mast
lineage in both populations is just above that of the E, B, M and the eo lineages. In
previous studies performed in this laboratory, a similar predominance of macrophage
lineage expression was noted (16-20). 1. Suda et al. concluded that the predominance of
expression of the macrophage lineage by progenitors cultured in the presence of PWMSCM could be due to a higher incidence or rate of production unique to the macrophage
lineage, or it could be due to an artifact caused by an increased ability of the macrophage
lineage to survive and proliferate in their culture system (14).
In conclusion, culture of enriched hemopoietic progenitors from normal and 5-FUtreated mice in maximally permissive culture systems has resulted in data that casts doubt
on the validity of the conventional model of hemopoietic differentiation which postulates an
early divergence of common myeloid and common lymphoid progenitors in hemopoiesis.
Further, these observations support a stochastic model of the random restriction of lineage
potential of differentiating progenitors. However, conclusions concerning the presence of
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a bipotential B-Iymphoid/macrophage progenitor rely on the assumption that these assays
are equally pennissive for the expression and identification of all lineages.
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Table 4-1. Myeloid and B-Iymphoid Lineage Expression of Individual Lin- Sca-1 +
Progenitors from normal mice

Number of colonies
B-Iym~hoid

Myeloid expression
nm
m
nmEMastMeo
nmMast
nmEMastM
nmMasteo
nmeo
nmEMasteo
nmMastM
nmM
nmE

mEMastM
nmEM
nmEMast
mMast
n
None

56
39
9

7
7
5
5
4
3
1
0
0
1
1

1
1

eX12ression

+

Total

13
8
1

69

3

1
1

1
2
0
1
1
1

0
0
0
0
9

47

10
10
8
6
6

6
3
2

1
1
1
1
1

Percentage
with B-lymphoid
lineage expression

19
17
10
30
13
14

17
33
0
50
100
100

1

0
0
0
0

9

100

Lin- Sca-l + progenitors isolated from normal mice were plated in primary MTC culture
containing SF, IL-7, Ep, and IL-l1, on day 8 all colonies present were harvested and
divided into liquid myeloid culture containing IL-3, SF, IL-5 and Ep and liquid lymphoid
culture containing SF and IL-7. Liquid myeloid cultures were examined on days 4, 6 and 8
of secondary culture, while liquid lymphoid cultures were subjected to flow cytometric
analysis for the presence of B-220+ cells on day 11 or 12 of secondary culture.
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Table 4-2.

Myeloid and B-Iymphoid Lineage Expression of Individual Lin- Sca-l +
Progenitors from Mice Treated with 5-FU

Number of colonies
B-Iymphoid expression
Myeloid expression
nmEMastM
nm
nmEMast
nmMast
nmMastM
nmEMastMeo
nmMasteo

nmEM
nmEMasteo
nmMastMeo
nmE
nM
m

11
4
3
5

+

Total

5
7
5

16
11

Percentage
with B-Iymphoid
lineage expression

31
64

3
1
2

3
1
2

8
6
5
4
3

66

0

2

0

0

1

1

100

1

0
0

1

0
0

2

1
0
2

1

1

1

1

0

2

62

16
60
25

100
0

Lin- Sca-l + progenitors isolated from 5-FU-treated mice were plated in primary MTC
culture containing SF, IL-7, Ep, and IL-l1, on day 11 all colonies present were harvested
and divided into liquid myeloid culture containing PWM-SCM, 1L-3 and Ep and semisolid
lymphoid culture containing SF and IL-7. Liquid myeloid cultures were examined on days
2, 4 and 6 of secondary culture, while lymphoid cultures were examined for the presence
of pre-B cell colonies on day 11 or 12 of secondary culture.
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Table 4-3. Myeloid Lineage Expression by the Lymphohemopoietic Progenitors from
Normal and 5-FU-Treated Mice
Number of myeloid
lineages expressed

Percent of lymphohemopoietic pro~enitors
Normal
5-FU-treated

3 or more

36

69

2 (nm)

39

27

1 (m)

24

o

Data shown in Tables 4-1 and 4-2.
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Table 4·4. Incidence of Lineage Expression by the Population of Lin-Sca-1 + Progenitors
from Normal and 5-FU-Treated Mice

Lineage
expressIon

Percent of progenitors
Normal
5-FU-treated

m

100

100

n

73

97

Mast

26

72

E

16

52

M

13

48

B

18

43

eo

15

17

Data shown in Tables 4-1 and 4-2.

Figure 4-1. Modified view of hemopoietic differentiation based on a stochastic model of random lineage restriction, Ogawa et

al. In: Leukemia: Recent Advances in Biology and Treatment pages 391-397, 1985. Alan R Liss Inc., 150 Fifth Avenue, New
York, NY 10011. The population represents the cells isolated from marrow on aspiration. The darkly shaded cells are cells
those removed by density centrifugation, lineage selection and sorting for the Sca-l antigen. The remaining population
encompasses the populations of lin- Sca-l + progenitors from both normal and 5-FU treated mice. The lightly shaded cells are
those Lin- Sca-1 + progenitors that are sensitive to the cytotoxic effects of 5-FU. The abbreviations are the same as designated in
Figure 4-1.

Lin- Sca-l + progenitors, shaded cells are
sensitive to the cytotoxic effects of 5-FU.

8
@~.@ •. 8
8

More mature and mature cells removed by density
gradient centrifugation and lineage selection.
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Sillv1MARY

As discussed by Metcalf, one of the most important issues of which we must
always remain cognizant, when interpreting the in-vitro and in-vivo culture data of
hemopoietic progenitors, is the permissiveness of the assay (1). The permissiveness is the
ability of a culture assay to support the differentiation of all myeloid and lymphoid lineage
cells. The permissiveness is of vital importance, since our inferences concerning the
lineage potential and stage of differentiation of a progenitor or a population of progenitors
are based solely on our ability to identify the progeny to which the progenitor gives rise.
For example, in the first quantitative assay for hemopoietic progenitors, the spleen colony
assay (2), the colony forming units designated CFU-S were initially thought to be myeloid
restricted progenitors. However, further studies in pennissive conditions revealed that
many CFU-S are indeed pluripotent (3). As is evident, the major limiting factor of the
inferences made about the lineage potential of a progenitor of interest is the permissiveness
of the culture system in which it is being studied.
The two-step assay for lymphohemopoietic progenitors of Hirayama, was the first
assay capable of the clonal identification of progenitors with B-Iymphoid and myeloid
lineage potential that was not dependent on stromal cell support (4). The single-step assay
for lymphohemopoietic progenitors is a modified version of the two-step assay (5). Both
assays are capable of the quantitative identification of lymphohemopoietic progenitors.
Alone, each has limitations, but when used in conjunction these limitations can be
overcome. For example, identification of the myeloid and B-Iymphoid lineage potential of
a progenitor of interest in the two-step assay requires the time consuming harvest and
division of each primary colony into specific myeloid and B-Iymphoid cultures. This
process becomes a limitation if the progenitor of interest in the initial pool of colony
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forming progenitors cultured is present at a low incidence. The single-step assay, on the
other hand, requires that only potentially positive colonies be harvested for flow cytometric
analysis at the completion of the culture period. Thus, one advantage of the single-step
assay is the accurate identification and study of populations of progenitors with low
numbers of lymphohemopoietic and or lymphoid progenitors. Unfortunately, it is
impossible to serially examine colonies of interest when using the single-step assay as is
done in the two step assay. Since myeloid lineage expression of an individual progenitor is
examined at only one time point, identification of the complete myeloid lineage expression
of a progenitor although possible, is in some cases not as accurate as by the two-step assay
due to the kinetics of the appearance and disappearance of the individual myeloid lineages.
In using the single-step and the two-step assays to address the hypothesis:
"Commitment to the individual myeloid and the B-Iymphoid lineages occurs randomly as a
single event rather than as two events, commitment to myeloid and lymphoid lineage and
later commitment of myeloid and lymphoid restricted progenitors to the individual myeloid
and lymphoid lineages." I have been able to draw three major conclusions. First, a
significant population of lymphohemopoietic progenitors exists in nonnal mice that appears
to be rapidly proliferating (5). This conclusion is supported by two observations: a
population of lymphohemopoietic progenitors present in nonnal mice does not require the
presence of an early acting triggering factor to initiate and support lymphomyeloid colony
formation; and treatment of mice with 5-FU decreases the number of lymphohemopoietic
progenitors present in the bone marrow to approximately one-fourth the number present in
normal mouse bone marrow. The second conclusion is that IL-3 positively modulates the
proliferation lymphohemopoietic progenitors while inhibiting expression of the B-lymphoid
lineage (6). This conclusion is supported by the observation that 48 hour exposure of
proliferating lymphohemopoietic progenitors to IL-3 increased the number of clonable Blymphoid progenitors formed when compared with cultures not containing IL-3. While
exposure of proliferating early B-Iymphoid progenitors to IL-3 for 48 hours abrogated the
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expression of the B-Iymphoid lineage in secondary culture. An additional observation of
lymphohemopoietic progenitors cultured in IL-3 containing conditions was that the total
amount of proliferation of lymphohemopoietic progenitors was decreased, in the presence
of an increased rate of proliferation, compared to control cultures without IL-3. The
decreased amount of total proliferation can be attributed to the presence of a shorter
duration of proliferation of lymphohemopoietic progenitors prior to their commitment,
suggesting that IL-3 may provide a stimulus to increase the rate of cellular proliferation and
differentiation at the expense of self-renewal. Finally, I was able to conclude that the
expression of the B-Iymphoid and the myeloid lineages by the population of Lin- Sca-1 +
progenitors isolated from normal mice is consistent with the previously established
stochastic model of the random loss of lineage potential by individual progenitors (7). This
conclusion was supported by the observation that regardless of the number or the type of
myeloid lineages expressed by an individual progenitor, approximately 18% of the
progenitors gave rise to the B-Iymphoid lineage. These observations are very similar to the
previous observations of Nakahata et ai., T. Suda et ale and J. Suda et al. in which the
myeloid lineage expression of individual blast cells and micromanipulated daughter cells
was found to be highly heterogeneous which form the foundation of the stochastic model
of cell commitment (8-12). In conducting these investigations an apparent association
between the B-Iymphoid and the macrophage lineage also appeared to be present, as has
been postulated by several other investigators. Together, these results support a model of
random restriction of lineage potential with a late divergence of the B-Iymphoid and the
myeloid lineages, possibly resulting in the formation of a bipotential Blymphoid/macrophage progenitor.
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A MODEL OF EARLY B-LYMPHOPOIESIS

As discussed in Chapter I, Cumano et al. proposed a model of B-Iymphopoiesis by
progenitors isolated from murine fetal liver. Briefly, their model included seven phases of
B-Iymphopoiesis: phase I was comprised of primitive lymphohemopoietic progenitors;
phase II, bipotential B-Iymphoidlmacrophage expressing AA4 and Ly-6A; phase III, B220
positive B cell progenitors; phase IV, B220 positive B cell progenitors no longer requiring
IL-7; and phases V -VII are composed of maturing B-Iymphoid cells expressing surface Ig.
Although this model incorporates a bipotential B-Iymphoid/macrophage progenitor, it
emphasizes the stages of differentiation positive for the expression of the B220 surface
antigen. In the model of B-Iymphopoiesis which I will now propose, emphasis is placed
on the elucidation of the stages of differentiation prior to the expression of the B220 surface
antigen. In this model, Figure 5-1, B-Iymphopoiesis is hypothesized to progress through 4
stages: 1) the lymphohemopoietic progenitor (LHP) proliferative stage; 2) the commitment
stage; 3) the early committed B-Iymphoid proliferative stage; and 4) the B220+ maturation
stage as has been exquisitely characterized by Hardy et al. (13) and is included for
completeness.

Stage 1: The LHP proliferative stage.
Primiti ve LHP in this model are those that are present in the population of Lin- Seal + progenitors from 5-FU treated mice. The cytokines required for the initiation and
support of proliferation by these progenitors have been well studied. They require the
synergistic interaction of an early acting triggering factor and an intennediate acting
supporting factor, IL-l1 and SF for example. Recently, 3 investigators have independently
studied the effects of the recently cloned cytokine, flt3/flk2 ligand (FL), on the proliferation
and differentiation of primitive hemopoietic progenitors (16, 17) and primitive
lymphohemopoietic and committed B-Iymphoid progenitors (18). They all observed
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somewhat similar result suggesting that FL synergistically supports the proliferation of
primitive progenitors while also maintaining them in a somewhat undifferentiated state. As
has been defined, the LHP proliferative stage has an approximate duration of 6 days (6).
Near the end of this stage, progenitors which I have designated "late stage LHP", are
fonned. The LHP isolated from normal mice reside at various points within the LHP
proliferative stage. A unique characteristic of some late stage LHP is that they do not
require an early acting triggering factor to initiate proliferation and support colony
formation. However, IL-II does have a positive synergistic effect and addition increases
colony size. As was evident from experiments with LHP isolated from normal mice, the
addition of IL-II to SF resulted in a synergistic increase in colony formation by these
progenitors, and thus, perhaps not all late stage LHP are capable of proliferation and
colony formation in the absence of IL-ii.

Sta~e

2: The commitment stage.
Following the LHP proliferative stage and the formation of late stage LHP, is the

commitment stage. In this stage B220- B-Iymphoid progenitors are generated by LHP as
the LHP disappear. As discussed, some controversy as to the lineage potential of the late
stage LHP and the divergence of the B-Iymphoid and the myeloid lineages exists, be it
from pluripotent lymphohemopoietic or bipotential B-Iymphoid/macrophage progenitors.

Staie 3: The early committed B-Iymphoid proliferative stage.
With the formation of B220- B-Iymphoid progenitors, the early committed Blymphoid proliferative stage begins. This stage is ultimately characterized by B-Iymphoid
progenitors that do not express B220. It is this stage of B-Iymphopoiesis which is least
well understood, and most difficult to study due to the low incidence of progenitors and the
lack of known specific markers for cells in this stage. Of major interest, is the duration of
this stage and the response of cells in this stage to cytokines and combinations of
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cytokines. Hirayama et al. observed that FL was capable of supporting the differentiation
of B220- B-Iymphoid progenitors into B220+ progenitors, and that FL and SF synergized
enhancing the formation of B220+ cells from B220- cells. Neither SF or IL-7 alone was
capable of supporting the formation of B220+ cells from B220- cells while in combination
they readily supported this differentiation. From this, one could postulate that FL may
support an intermediate B220- progenitor and its differentiation. Another interesting
observation is the extremely inhibitory effect of IL-3 on B-Iymphoid progenitors in the
early committed B-Iymphoid proliferative stage. We know that IL-3 is very toxic to the
earliest committed B220- B-Iymphoid progenitors. However, we have been unable to
definitively determine the effect, if any, of IL-3 on the commitment of lymphohemopoietic
progenitors to the B-Iymphoid lineage. We are currently unable to identify when the
expression ofB220 by B220- B-Iymphoid progenitors begin to occur, therefore, we cannot
draw a firm conclusion as to the effect of IL-3 on the B220+ pro-B cells as is represented
by the dashed lines.

Stage 4: The B220+ maturation stage.
The substages of the B220+ maturation stage have been well defined as has been
discussed in Chapter 1. The earliest B220+ progenitors have been shown to express B220
at very low levels (14-15). Interestingly, the earliest B220+ pro-B cells have been shown
to be negative for both c-kit and IL-7 receptor expression (19) and non-dependent on these
factors (20). However, the combination of SF, IL-7 and Ep in the single-step assay has
been shown to support the fonnation ofpre-B cell colonies by lymphohemopoietic and
B220- committed B-Iymphoid progenitors from normal mice. It could be argued that
further differentiation fonn B220- to B220+ requires an additional factor which accessory
cells present in the culture may provide in addition to SF and IL-7.
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PROPOSED FUTURE INVESTIGATION

The staging of progenitors in B-Iymphopoiesis.
As discussed in the introduction, a great deal of information about B-Iymphoid
progenitors expressing B220 has been compiled. Far less is known about the stages of Blymphopoiesis prior to the expression ofB220 including late stage lymphohemopoietic
progenitors and B220- B-Iymphoid progenitors. I have begun characterization of these less
well known stages ofB-lymphopoiesis, and I have outlined a model ofB-lymphopoiesis
by primitive lymphohemopoietic progenitors.
A population of B220- committed B-Iymphoid progenitors is believed by many to
give rise to B220+ progenitors. In 1986 Muller-Sieberg et al. in examining early Blymphopoiesis utilized FACS sorting to isolate a population ofB220- cells from murine
bone marrow (21). This population ofB-lymphoid progenitors was considered a more
primitive popUlation of B-Iymphoid progenitors than those present in the B220+ fraction of
bone marrow. Later, McNiece et aI. isolated a similar population ofB220- progenitors
from bone marrow in their investigation of the role of SF in early B-Iymphopoiesis (22).
Once again, this population was isolated in the belief that the B220- progenitors present in
bone marrow were more primitive B-Iymphoid progenitors than those present in the B220+
fraction. Most recently, Hirayama et al. in their investigations of the role of flt3/flk2 ligand
on early B-Iymphopoiesis by committed B-Iymphoid progenitors, isolated a population of
Mac-l-, TERl19-, Ly-2-, L3T4- andB220- cells (18). This population was once again
considered to be a more primitive population of B-Iymphoid progenitors than the B220+
popUlation.
Recent unpublished studies directed at enriching primitive popUlations of B220 BM

lymphoid progenitors using B220 staining and flow cytometric analysis and sorting,
indicate there is no enrichment of early committed B-Iymphoid progenitors in the B22010w
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population of committed B-Iymphoid progenitors in the early committed B-Iymphoid
proliferative stage. Future investigations focusing on: 1) the enrichment of
lymphohemopoietic progenitors within the various stages, 2) the cytokine requirements of
progenitors in the stages of differentiation and 3) the examination and characterization of
the progenitors present in fetal, neonatal and adult animals will contribute to a more clear
understanding of the processes of B-Iymphopoiesis. In pursuing these investigations the
following hypothesis should be addressed: "There are several definable and identifiable
stages of B-Iymphopoiesis prior to the stages characterized by the expression of the B-220
surface antigen." Emphasis should be placed on three specific aims: the demonstration and
isolation of late stage lymphohemopoietic and B220- committed B-Iymphoid progenitors;
definition of the stages in which they are present; and modeling of these early processes of
B-Iymphopoiesis.

Figure 5 .. 1. Model of hemopoietic differentiation of lymphohemopoietic progenitors in adult marrow. Primitive
lymphohemopoietic progenitors pass through 4 stages in the formation ofB220+ pre-B cells in culture. The stage designated the
B220+ maturation stage has been well elucidated by Hardy et ale J. Exp. Med. 173; 1213-1225, 1991. The stages prior to the
B220+ maturation stage have been characterized using the two-step and the single-step assays for lymphohemopoietic
progenitors.
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